Amedeo Smart

Free Medical Literature Service

 

Amedeo

Nuclear Medicine
  Free Subscription

Articles published in
J Nucl Med
    September 2025
  1. VEIT-HAIBACH P
    Reply: Making Green Nuclear Medicine and Radiotheranostics Real in a Developing Country.
    J Nucl Med. 2025 Sep 18:jnumed.125.270767. doi: 10.2967/jnumed.125.270767.
    >> Share

  2. DUAN X, Sarkar S, Lyo V, Romeo S, et al
    Quantification of (18)F-FDG Delivery Rate for Liver Inflammation Using Shortened Dynamic PET Imaging Protocols.
    J Nucl Med. 2025 Sep 18:jnumed.124.269434. doi: 10.2967/jnumed.124.269434.
    >> Share

  3. MALDONADO SP, Pedraza CM, Forero PA, Yepes MM, et al
    Making Green Nuclear Medicine and Radiotheranostics Real in a Developing Country.
    J Nucl Med. 2025 Sep 18:jnumed.125.270499. doi: 10.2967/jnumed.125.270499.
    >> Share

  4. SHIYAM SUNDAR LK, Gutschmayer S, Pires M, Ferrara D, et al
    Fully Automated Image-Based Multiplexing of Serial PET/CT Imaging for Facilitating Comprehensive Disease Phenotyping.
    J Nucl Med. 2025 Sep 18:jnumed.125.269688. doi: 10.2967/jnumed.125.269688.
    >> Share

  5. WEIBERG D, Wilhelm LM, Felgenhauer T, Ross T, et al
    (68)Ga-FAPI-46 PET/CT in Primary Sclerosing Cholangitis and Suspected Cholangiocarcinoma.
    J Nucl Med. 2025 Sep 18:jnumed.125.270434. doi: 10.2967/jnumed.125.270434.
    >> Share

  6. DIEKMANN J, Konig T, Hess A, Zwadlo C, et al
    CXCR4 PET/CT Predicts Left Ventricular Recovery 8 Months After Acute Myocardial Infarction.
    J Nucl Med. 2025 Sep 18:jnumed.125.270807. doi: 10.2967/jnumed.125.270807.
    >> Share

  7. PACKARD RRS, Maddahi J, Pelletier-Galarneau M, Al-Mallah MH, et al
    SNMMI/EANM/ASNC/ACNM Procedure Standard/Practice Guideline for (18)F-Flurpiridaz PET Myocardial Perfusion Imaging and Blood Flow Quantitation.
    J Nucl Med. 2025 Sep 18:jnumed.125.270873. doi: 10.2967/jnumed.125.270873.
    >> Share

  8. HOSSEINI A, Haj-Yehia E, Korste S, Kuzay Y, et al
    How Rapidly Does the FAPI PET Signal Reverse Following Therapy? Assessing the FAPI PET Signal in Hypertensive Cardiac Injury and Fibrosis in Mice.
    J Nucl Med. 2025 Sep 11:jnumed.124.268860. doi: 10.2967/jnumed.124.268860.
    >> Share

  9. KUNSCH J, Zaragori T, Olivier P, Claudin M, et al
    Prognostic Value of Comprehensive Analysis of Metastatic Prostate Tumor Changes from First to Last [(177)Lu]Lu-PSMA Therapy Injections Through Serial High-Speed Whole-Body 360 degrees Cadmium-Zinc-Telluride SPECT.
    J Nucl Med. 2025 Sep 11:jnumed.125.270358. doi: 10.2967/jnumed.125.270358.
    >> Share

  10. BEINTNER-SKAWRAN S, Gafita A, Lorenzini T, Tauber R, et al
    [(68)Ga]Ga-PSMA-11 PET Tumor Volume Predicts Overall Survival of Patients with Metastatic Prostate Cancer Undergoing Taxane-Based Chemotherapy.
    J Nucl Med. 2025 Sep 11:jnumed.125.269584. doi: 10.2967/jnumed.125.269584.
    >> Share

  11. VERA P, Calais J
    From Nuclear Medicine Specialist to Cancer Center Director: Jeremie Calais Talks with Pierre Vera about Leading Through Change in Nuclear Medicine.
    J Nucl Med. 2025 Sep 11:jnumed.125.270978. doi: 10.2967/jnumed.125.270978.
    >> Share

  12. ZHOU IY, Zhang C, Sojoodi M, Rotile NJ, et al
    (18)F-FPP-RGD(2) PET Imaging for Interrogating Target Engagement and Antifibrotic Activity of an Integrin Antagonist in a Mouse Model of Metabolic Dysfunction-Associated Steatohepatitis.
    J Nucl Med. 2025 Sep 11:jnumed.125.270047. doi: 10.2967/jnumed.125.270047.
    >> Share

  13. URIBE C, Iravani A, Savir-Baruch B, Jacene H, et al
    Summary: SNMMI/ACNM Procedure Standard for Posttreatment Imaging of (177)Lu-Based Radiopharmaceuticals.
    J Nucl Med. 2025 Sep 11:jnumed.125.270979. doi: 10.2967/jnumed.125.270979.
    >> Share

  14. EBNER R, Braach J, Rubenthaler J, Cyran CC, et al
    Retrospective Evaluation of the Correlation Between Somatostatin Receptor PET/CT and Histopathology in Patients with Suspected Intracranial Meningiomas.
    J Nucl Med. 2025 Sep 11:jnumed.125.270115. doi: 10.2967/jnumed.125.270115.
    >> Share

  15. YOO HB, Kang SK, Shin SA, Kim D, et al
    Artificial Intelligence-Powered Quantification of Flortaucipir PET for Detecting Tau Pathology.
    J Nucl Med. 2025 Sep 11:jnumed.125.269636. doi: 10.2967/jnumed.125.269636.
    >> Share

  16. VISSER D, Golla SSV, Palard-Novello X, Verfaillie SCJ, et al
    Varying Levels of Inflammatory Activity in Brain and Body of Patients with Persistent Fatigue and Difficulty Concentrating After COVID-19: A TSPO PET Study.
    J Nucl Med. 2025 Sep 11:jnumed.124.269297. doi: 10.2967/jnumed.124.269297.
    >> Share

  17. SMITH R, Garibotto V, Hagerstrom D, Jogi J, et al
    Evaluation of a Sensitive Visual Read Algorithm for Assessing 3R/4R Tau PET Images.
    J Nucl Med. 2025 Sep 4:jnumed.125.269685. doi: 10.2967/jnumed.125.269685.
    >> Share

  18. GRAVEL P, Gu J, Wang C, Volpi T, et al
    Toward Imaging of the GABA Transporter Type 1 In Vivo: Quantitative Evaluation of 4 Novel PET Radiotracers in Nonhuman Primates.
    J Nucl Med. 2025 Sep 4:jnumed.125.270332. doi: 10.2967/jnumed.125.270332.
    >> Share

  19. PANDIT-TASKAR N, Basu E, Pirasteh A, Behr G, et al
    Lesion Analysis of (18)F-Metafluorobenzylguanidine PET Imaging in Neuroblastoma.
    J Nucl Med. 2025 Sep 4:jnumed.125.269833. doi: 10.2967/jnumed.125.269833.
    >> Share

  20. HUANG B, Dai B, Lapi SE, Liles G, et al
    High-Resolution Positronium Lifetime Tomography at Clinical Activity Levels on the PennPET Explorer.
    J Nucl Med. 2025;66:1464-1470.
    >> Share

  21. CHEN L, Rizzo G, Bulawa C, Van Dijk KRA, et al
    Evaluation of Mitochondrial Complex 1 Density with [(18)F]BCPP-EF in a Murine Model and Individuals with Friedreich Ataxia.
    J Nucl Med. 2025;66:1434-1439.
    >> Share

  22. LANZAFAME H, Heilig CE, Wardelmann E, Desaulniers M, et al
    (90)Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous Tumors.
    J Nucl Med. 2025;66:1378-1384.
    >> Share

  23. HOOIVELD-NOEKEN JS, de Ruijter LK, van de Donk PP, Smit LM, et al
    Heterogeneity of CD8 T-Cell Changes in Advanced Melanomas After Initiation of Immunotherapy.
    J Nucl Med. 2025;66:1345-1351.
    >> Share

  24. VAN BINSBERGEN WH, Zwezerijnen GJC, Windhorst AD, Schober P, et al
    SUVs Versus Dynamic Pharmacokinetic [(18)F]Fluoro-Polyethylene Glycol-Folate Uptake Parameters in Joints of Rheumatoid Arthritis Patients at Baseline and at 4 Weeks of Antitumor Necrosis Factor Therapy.
    J Nucl Med. 2025;66:1458-1463.
    >> Share

    August 2025
  25. ALTUNAY B, Schafer L, Morgenroth A, Pena Q, et al
    Combining PSMA-Targeted Radiopharmaceutical Therapy with Immunotherapy.
    J Nucl Med. 2025 Aug 28:jnumed.125.270317. doi: 10.2967/jnumed.125.270317.
    >> Share

  26. STAMMES MA, Koopman G, Wagner TR, Traenkle B, et al
    Noninvasive Monitoring of Inflammatory Processes by Myeloid Cell-Directed PET Tracers in an Experimental Severe Acute Respiratory Syndrome Coronavirus 2 Infection Model.
    J Nucl Med. 2025 Aug 28:jnumed.125.269721. doi: 10.2967/jnumed.125.269721.
    >> Share

  27. ROYA M, Tsoumpas C, van Snick JH, Dao V, et al
    Impact of Ultrahigh Sensitivity and Continuous Bed Motion on Performance Characteristics of Biograph Vision Quadra PET/CT.
    J Nucl Med. 2025 Aug 28:jnumed.125.270078. doi: 10.2967/jnumed.125.270078.
    >> Share

  28. LI X, Zhao Y, Hsu JC, Sarduy EA, et al
    [(44)Sc]Sc-CHX-A''-DTPA-RCCB6: A PET Tracer for Imaging CD70 Expression Across Latency Types of Burkitt Lymphoma.
    J Nucl Med. 2025 Aug 28:jnumed.125.269991. doi: 10.2967/jnumed.125.269991.
    >> Share

  29. WANG S, Lu Y, Xue Y, Han H, et al
    Serial [(18)F]AlF-NOTA-FAPI PET/CT and CT Angiography in Type B Aortic Dissection Before and After Thoracic Endovascular Aortic Repair.
    J Nucl Med. 2025 Aug 21:jnumed.125.270511. doi: 10.2967/jnumed.125.270511.
    >> Share

  30. FLAUS A, Levigoureux E, Haesebaert J, Briet C, et al
    Prospective Multicenter Evaluation of [(11)C]Methionine PET/MRI Sensitivity Compared with MRI for Localizing Small Pituitary Neuroendocrine Tumor or Pituitary Adenoma in Cushing Disease.
    J Nucl Med. 2025 Aug 21:jnumed.124.269392. doi: 10.2967/jnumed.124.269392.
    >> Share

  31. RYU J, Han S, Yoo TR, Lee SB, et al
    Diagnostic Performance of (18)F-Fluoroestradiol PET/CT for Axillary Lymph Node Metastasis in Invasive Lobular Carcinoma: A Prospective Feasibility Study.
    J Nucl Med. 2025 Aug 14:jnumed.125.269573. doi: 10.2967/jnumed.125.269573.
    >> Share

  32. SCHILLER F, Brumberg J, Frings L, Deschamps J, et al
    Clinical Validation of Deep Learning for Image Restoration of Ultra-Low-Count [(18)F]FDG PET for Dementia Diagnostics.
    J Nucl Med. 2025 Aug 14:jnumed.124.269234. doi: 10.2967/jnumed.124.269234.
    >> Share

  33. MINGELS C, Chung KJ, Nalbant H, Abdelhafez YG, et al
    Lymphoma Therapy Response Assessment with Low-Dose [(18)F]FDG Total-Body PET/CT.
    J Nucl Med. 2025 Aug 14:jnumed.124.268841. doi: 10.2967/jnumed.124.268841.
    >> Share

  34. JACOBSON O, Zhang HH, Olkowski CP, Ghaemi B, et al
    Monitoring T-Cell Activation in the Tumor Microenvironment by PET Imaging of the Chemokine CXCL9.
    J Nucl Med. 2025 Aug 14:jnumed.125.269795. doi: 10.2967/jnumed.125.269795.
    >> Share

  35. PACKARD RRS, Buckley C, Cooke CD, Moody JB, et al
    Comparison, Agreement, and Significance Cutoffs of (18)F-Flurpiridaz PET Myocardial Blood Flow Quantitation Methods and Software Packages.
    J Nucl Med. 2025 Aug 7:jnumed.124.269398. doi: 10.2967/jnumed.124.269398.
    >> Share

  36. GRKOVSKI M, Krebs SS, O'Donoghue JA, Kuten J, et al
    Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [(177)Lu]Lu-PSMA-617 Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Aug 7:jnumed.125.270170. doi: 10.2967/jnumed.125.270170.
    >> Share

  37. RIKKEN RM, van de Giessen E, Brumberg J, Aarnio R, et al
    Imaging Proinflammatory Microglia in Parkinson Disease Using [(11)C]SMW139 PET: A Multicenter Study.
    J Nucl Med. 2025 Aug 7:jnumed.125.269671. doi: 10.2967/jnumed.125.269671.
    >> Share

  38. HUANG W, Li L, Chao F, Yang Q, et al
    [(64)Cu]Cu-NOTA-EV-F(ab')(2) Enables Same-Day Immuno-PET Imaging of Nectin-4 in Triple-Negative Breast and Urothelial Bladder Cancers.
    J Nucl Med. 2025 Aug 7:jnumed.125.270132. doi: 10.2967/jnumed.125.270132.
    >> Share

  39. ENKE JS, Schuller BW, Glantschnig L, Kircher M, et al
    Biodistribution and Radiation Dosimetry for [(68)Ga]Ga-LNTH-1363S, a Probe Targeting Fibroblast Activation Protein alpha.
    J Nucl Med. 2025;66:1284-1290.
    >> Share

  40. CARSON R
    2024 SNMMI Highlights Lecture: Neurosciences.
    J Nucl Med. 2025;66:1176-1183.
    >> Share

  41. BOELLAARD R, Rahmim A, Eertink JJ, Duehrsen U, et al
    Summary Report of the SNMMI AI Task Force Radiomics Challenge 2024.
    J Nucl Med. 2025;66:1169-1175.
    >> Share

    July 2025
  42. MAKALA H, Sheehan-Klenk J, Lee W, Chung JY, et al
    CD24 as a Novel Radiopharmaceutical Target for Hepatocellular Carcinoma.
    J Nucl Med. 2025 Jul 31:jnumed.125.270167. doi: 10.2967/jnumed.125.270167.
    >> Share

  43. DENIS CS, Cousin F, De Laere B, Vanwelkenhuyzen J, et al
    Assessing Interlesional Tumor Response and Patient Outcomes with Sequential PSMA PET/CT in Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Jul 31:jnumed.125.269729. doi: 10.2967/jnumed.125.269729.
    >> Share

  44. KALITA M, Kuo RC, Reyes ST, Colburg DRC, et al
    Advancing In Vivo Detection of T-Cell Function: Development and Preclinical Evaluation of (89)Zr-Ivuxolimab, a Human OX40 PET Tracer.
    J Nucl Med. 2025 Jul 24:jnumed.125.269799. doi: 10.2967/jnumed.125.269799.
    >> Share

  45. BUNNING S, Christodoulou D, Cohen JE, Cutler CS, et al
    Proceedings: PET Drugs-A 2023 Workshop on Product Quality, Regulatory Submissions, Facility Inspections, and Benefit-Risk Considerations.
    J Nucl Med. 2025 Jul 24:jnumed.125.270011. doi: 10.2967/jnumed.125.270011.
    >> Share

  46. CHEN B, Zheng C, Balayeva T, Toyonaga T, et al
    [(18)F]SynVesT-1 PET Detects SV2A Changes in the Spinal Cord and Brain of Rats with Spinal Cord Injury.
    J Nucl Med. 2025 Jul 17:jnumed.124.269291. doi: 10.2967/jnumed.124.269291.
    >> Share

  47. DERLIN T, Hanke JS, Werner RA, Ziegler SI, et al
    Characterization of Left Ventricular Assist Device-Specific Infection by Whole-Body Parametric PET Imaging.
    J Nucl Med. 2025 Jul 17:jnumed.125.270252. doi: 10.2967/jnumed.125.270252.
    >> Share

  48. CHEN Y, Zhang X, Wang X, Liu Y, et al
    Interspecies Variability in Biodistribution and PET Imaging Performance of [(18)F]Di-PyL: A Dimeric, PSMA-Targeted PET Agent for Prostate Cancer.
    J Nucl Med. 2025 Jul 17:jnumed.125.270069. doi: 10.2967/jnumed.125.270069.
    >> Share

  49. BRADSHAW TJ, Brosch-Lenz J, Uribe C, Karakatsanis N, et al
    Recommendations for Standardizing Nuclear Medicine Terminology and Data in the Era of Theranostics and Artificial Intelligence.
    J Nucl Med. 2025 Jul 10:jnumed.124.269424. doi: 10.2967/jnumed.124.269424.
    >> Share

  50. DAKANALI M, Zigler SS, Schwarz SW, Nickels ML, et al
    Reply to "Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals".
    J Nucl Med. 2025 Jul 10:jnumed.125.270467. doi: 10.2967/jnumed.125.270467.
    >> Share

  51. PLYKU D, Koo H, Park L, Hofling A, et al
    Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals.
    J Nucl Med. 2025 Jul 10:jnumed.125.270320. doi: 10.2967/jnumed.125.270320.
    >> Share

  52. SCHAEFER R, Kunze LH, Haertel M, Zhu Y, et al
    Image-Derived Blood Normalization of Antibody-Based TREM2 PET in Mouse Models of Amyloidosis and Myocardial Infarction.
    J Nucl Med. 2025 Jul 10:jnumed.125.269472. doi: 10.2967/jnumed.125.269472.
    >> Share

  53. KURCH L, Landman-Parker J, Georgi TW, Attarbaschi A, et al
    Quantitative Deauville Scoring to Uncover Prognostic Information from (18)F-FDG PET-Based Response Assessment: Data from the EuroNet-PHL-C1 Trial.
    J Nucl Med. 2025 Jul 10:jnumed.125.269603. doi: 10.2967/jnumed.125.269603.
    >> Share

  54. KOHAN A, Metser U, Luke W, Rashid M, et al
    A Prospective Provincial Registry of (18)F-PSMA PET/CT for Recurrent Prostate Cancer: Results for 4,135 Men.
    J Nucl Med. 2025 Jul 3:jnumed.125.269653. doi: 10.2967/jnumed.125.269653.
    >> Share

  55. BANG YH, Kim JH, Kim YH, Kim HR, et al
    Distinct Prognostic Roles of (18)F-FDG PET Metabolic Response Assessed After Induction Chemotherapy or Chemoradiotherapy in Localized Esophageal Squamous Cell Carcinoma.
    J Nucl Med. 2025 Jul 3:jnumed.125.269775. doi: 10.2967/jnumed.125.269775.
    >> Share

  56. SUNDERLAND JJ, Boellaard R, Dickson JC, Graves SA, et al
    Standardization of PET/CT Performance Requirements for Whole-Body Quantitative Imaging: An International Proposal.
    J Nucl Med. 2025 Jul 3:jnumed.124.269349. doi: 10.2967/jnumed.124.269349.
    >> Share

  57. KASHYAP R, Buteau JP, Bressel M, Eifer M, et al
    Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [(177)Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials.
    J Nucl Med. 2025 Jul 3:jnumed.125.269640. doi: 10.2967/jnumed.125.269640.
    >> Share

  58. TAIEB D, Prior JO, Dierckx RAJO
    Embracing Flow: Exploring Panta Rhei in the Context of Nuclear Medicine.
    J Nucl Med. 2025 Jul 3:jnumed.125.270179. doi: 10.2967/jnumed.125.270179.
    >> Share

  59. CHAN DL, Hayes A, Karfis I, Conner A, et al
    [(18)F]FDG Metabolic Tumor Volume as a Prognostic Marker in Neuroendocrine Neoplasm: A Multicenter Study.
    J Nucl Med. 2025;66:1012-1017.
    >> Share

  60. STOKKEL MPM, Gotthardt M, Herrmann K, Gnanasegaran G, et al
    Theranostics in Perspective: White Paper.
    J Nucl Med. 2025;66:1007-1011.
    >> Share

    June 2025
  61. AHLSTROM A, Lindstrom E, Maaniittyy T, Iida H, et al
    Automated Total-Body Perfusion Imaging with (15)O-Water PET Using Basis Functions and Organ-Specific Model Selection.
    J Nucl Med. 2025 Jun 26:jnumed.124.269409. doi: 10.2967/jnumed.124.269409.
    >> Share

  62. SAYED A, Al Rifai M, Al-Mallah M
    Differential Association of PET-Derived Rest and Stress Myocardial Blood Flow with Cardiovascular Outcomes.
    J Nucl Med. 2025 Jun 18:jnumed.125.269457. doi: 10.2967/jnumed.125.269457.
    >> Share

  63. XIA Y, Dhaynaut M, Chemli Y, Lois C, et al
    Quantitative Measurement of Tau Burden in a Dual-Time-Window Dynamic PET Imaging Protocol with [(18)F]M6240.
    J Nucl Med. 2025 Jun 18:jnumed.125.270165. doi: 10.2967/jnumed.125.270165.
    >> Share

  64. JADVAR H, Atkins MB, Bartel T, de Geus-Oei LF, et al
    Summary: Appropriate Use Criteria for (18)F-FDG PET/CT for Initial Staging of Malignant Disease.
    J Nucl Med. 2025 Jun 18:jnumed.125.270429. doi: 10.2967/jnumed.125.270429.
    >> Share

  65. MOGENSEN AW, Torp-Pedersen C, Norgaard M, Petersen LJ, et al
    The Use of PSMA PET/CT Improves Overall Survival in Men with Biochemically Recurrent Prostate Cancer Treated with Salvage Radiotherapy: Real-World Data from an Entire Country.
    J Nucl Med. 2025 Jun 12:jnumed.125.269996. doi: 10.2967/jnumed.125.269996.
    >> Share

  66. BOBBA KN, Wadhwa A, Bidkar AP, Raveendran A, et al
    Evaluation of (134)Ce/(134)La-PSMA-617 for PET Imaging and Auger Electron Therapy of Prostate Cancer.
    J Nucl Med. 2025 Jun 12:jnumed.125.269751. doi: 10.2967/jnumed.125.269751.
    >> Share

  67. YUE J, Zhang Y, Miu Y, Zhao Y, et al
    Radiopharmaceutical Therapy: Balancing Absorbed Dose and Antitumor Immunity.
    J Nucl Med. 2025 Jun 12:jnumed.125.269868. doi: 10.2967/jnumed.125.269868.
    >> Share

  68. KWON D, Li EJ, Dulal C, Daube-Witherspoon M, et al
    Dual-Tracer Imaging on a Long-Axial-Field-of-View PET: A Proof-of-Principle Study with [(18)F]FGln and [(18)F]FDG.
    J Nucl Med. 2025 Jun 12:jnumed.124.268831. doi: 10.2967/jnumed.124.268831.
    >> Share

  69. DRZEZGA A, Barthel H
    Imaging and Fluid Biomarkers of Alzheimer Disease: Complementation Rather Than Competition.
    J Nucl Med. 2025;66.
    >> Share

  70. FANTI S, Robles Barba JJ, Behr S, Maurer T, et al
    Imaging Efficacy of [(18)F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath-A Phase 3, Prospective Multicenter Study.
    J Nucl Med. 2025 Jun 5:jnumed.124.269266. doi: 10.2967/jnumed.124.269266.
    >> Share

  71. IAGARU A, Suarez JF, Behr S, Aggarwal R, et al
    Imaging Efficacy of [(18)F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study.
    J Nucl Med. 2025 Jun 5:jnumed.124.269007. doi: 10.2967/jnumed.124.269007.
    >> Share

  72. GAFITA A, Schroeder JA, Ceci F, Oldan JD, et al
    Treatment Response Evaluation in Prostate Cancer Using PSMA PET/CT.
    J Nucl Med. 2025 Jun 5:jnumed.124.268071. doi: 10.2967/jnumed.124.268071.
    >> Share

  73. MANSUR A, McConathy JE, Stringer-Reasor E, Rocque G, et al
    Quantitative [(89)Zr]Zr-Trastuzumab PET and Diffusion- Weighted MRI for Characterization of Metastatic HER2-Positive Breast Cancer with PET/MRI.
    J Nucl Med. 2025 Jun 5:jnumed.124.268931. doi: 10.2967/jnumed.124.268931.
    >> Share

  74. COOLS R, Vermeulen K, Vonck E, Baekelandt V, et al
    In Vivo Visualization and Quantification of Brain Heat Shock Protein 90 with [(11)C]HSP990 in Healthy Aging and Neurodegeneration.
    J Nucl Med. 2025;66:940-947.
    >> Share

  75. KAYAL G, Roseland ME, Wang C, Fitzpatrick K, et al
    Multicycle Dosimetric Behavior and Dose-Effect Relationships in [(177)Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy.
    J Nucl Med. 2025;66:900-908.
    >> Share

    May 2025
  76. PALARD-NOVELLO X, Visser D, Yaqub M, van de Giessen E, et al
    Whole-Body [(18)F]DPA-714 Kinetic Assessment Using PET/CT Scanner with Long Axial Field of View.
    J Nucl Med. 2025 May 29:jnumed.124.268979. doi: 10.2967/jnumed.124.268979.
    >> Share

  77. LYNCH SE, Crawford C, Hunt AL, Sligh LL, et al
    Granzyme B PET Imaging Predicts Response to Immunotherapy in a Diet-Induced Obesity Model of Breast Cancer.
    J Nucl Med. 2025 May 29:jnumed.124.268938. doi: 10.2967/jnumed.124.268938.
    >> Share

  78. LILBURN DML, Garthwaite HS, Ganeshan B, Win T, et al
    [(18)F]FDG PET/CT Predicts Patient Survival in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
    J Nucl Med. 2025 May 29:jnumed.125.269497. doi: 10.2967/jnumed.125.269497.
    >> Share

  79. AKHAVANALLAF A, Lu Z, Peterson AB, Blakkisrud J, et al
    Can (177)Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data.
    J Nucl Med. 2025 May 22:jnumed.124.269098. doi: 10.2967/jnumed.124.269098.
    >> Share

  80. TRAUTWEIN NF, Mattern S, Hinterleitner M, Reischl G, et al
    Histologic Ex Vivo Validation of the [(18)F]SITATE Somatostatin Receptor PET Tracer.
    J Nucl Med. 2025 May 22:jnumed.125.269619. doi: 10.2967/jnumed.125.269619.
    >> Share

  81. RAMOS CD
    Redefining Nuclear Medicine: "Biodistribution" Should Be the Core Concept.
    J Nucl Med. 2025 May 22:jnumed.125.270245. doi: 10.2967/jnumed.125.270245.
    >> Share

  82. MOSTAFAPOUR S, van Sluis J, Lammertsma AA, Tsoumpas C, et al
    Reply to "(176)Lu Radiation in Long-Axial-Field-of-View PET Scanners: A Nonissue for Patient Safety".
    J Nucl Med. 2025 May 15:jnumed.125.270027. doi: 10.2967/jnumed.125.270027.
    >> Share

  83. ZHANG W, Yao W, Shen G
    [(68)Ga]Ga-FAPI PET/CT Monitors Response to Receptor Activator of Nuclear Factor-kappaB Ligand Inhibitor in a Giant Cell Tumor of Bone: Correlation with Histopathology.
    J Nucl Med. 2025 May 15:jnumed.124.269432. doi: 10.2967/jnumed.124.269432.
    >> Share

  84. CARTER LM, Milman R, Ocampo Ramos JC, Kesner AL, et al
    (176)Lu Radiation in Long-Axial-Field-of-View PET Scanners: A Nonissue for Patient Safety.
    J Nucl Med. 2025 May 15:jnumed.125.269846. doi: 10.2967/jnumed.125.269846.
    >> Share

  85. BAILEY DL, Meikle SR, Calamante F, Angelis G, et al
    The Australian National Total-Body PET Facility-A Shared Resource and Risk Model for Implementing Total-Body PET.
    J Nucl Med. 2025 May 15:jnumed.125.269859. doi: 10.2967/jnumed.125.269859.
    >> Share

  86. ZHAO Q, Liow JS, Jee JE, Montero Santamaria J, et al
    [(11)C]ZTP-1: An Effective Short-Lived Radioligand for PET of Rat and Monkey Brain Phosphodiesterase Type 4 Subtype B.
    J Nucl Med. 2025 May 8:jnumed.124.269159. doi: 10.2967/jnumed.124.269159.
    >> Share

  87. YEH R, Pareja F, Shobeiri P, Ross D, et al
    Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis.
    J Nucl Med. 2025 May 8:jnumed.124.269227. doi: 10.2967/jnumed.124.269227.
    >> Share

  88. DUBROFF JG, Hsieh CJ, Wiers CE, Lee H, et al
    [(11)C]Carfentanil PET Whole-Body Imaging of mu-Opioid Receptors: A First in-Human Study.
    J Nucl Med. 2025 May 8:jnumed.124.269413. doi: 10.2967/jnumed.124.269413.
    >> Share

  89. ICHIJO S, Arisawa T, Hatano M, Nakajima W, et al
    First-in-Human Study of (18)F-Labeled PET Tracer for Glutamate AMPA Receptor [(18)F]K-40: A Derivative of [(11)C]K-2.
    J Nucl Med. 2025 May 8:jnumed.124.269405. doi: 10.2967/jnumed.124.269405.
    >> Share

  90. ZARAGORI T, Chevalier E, Citerne Q, Roch V, et al
    Assessment of [(177)Lu]Lu-DOTATATE Dosimetry from High-Speed Whole-Body Recordings Provided by a 360 degrees Cadmium-Zinc-Telluride Camera Compared with Results from a Conventional Anger-Camera Protocol.
    J Nucl Med. 2025;66:771-777.
    >> Share

  91. PICHLER V, Schwingenschlogl-Maisetschlager V, Duman I, Monforte X, et al
    Bioanalytic Hybrid System Merging 3-Dimensional Cell Culture and Chromatographic Precision for Unprecedented Preclinical Insights in Molecular Imaging.
    J Nucl Med. 2025;66:813-816.
    >> Share

  92. TOURNIER N, Langer O
    Imaging the Activity of Efflux Transporters at the Blood-Brain Barrier in Neurologic Diseases: Radiotracer Selection Criteria.
    J Nucl Med. 2025;66:676-680.
    >> Share

    April 2025
  93. CHUNG KJ, Chaudhari AJ, Nardo L, Jones T, et al
    Quantitative Total-Body Imaging of Blood Flow with High-Temporal-Resolution Early Dynamic (18)F-FDG PET Kinetic Modeling.
    J Nucl Med. 2025 Apr 30:jnumed.124.268706. doi: 10.2967/jnumed.124.268706.
    >> Share

  94. FROEHNER M, Zophel K
    (177)Lu-PSMA Radiopharmaceutical Therapy or Cabazitaxel?
    J Nucl Med. 2025 Apr 30:jnumed.125.269875. doi: 10.2967/jnumed.125.269875.
    >> Share

  95. FELBER V, Holzleitner N, Joksch M, Suhrbier T, et al
    First-in-Human Serum Stability Studies of [(177)Lu]Lu-AMTG: A Step Toward Improved GRPR-Targeted Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Apr 30:jnumed.124.269132. doi: 10.2967/jnumed.124.269132.
    >> Share

  96. WENZEL M, Groener D, Chun FKH, Mandel P, et al
    Reply to "(177)Lu-PSMA Radiopharmaceutical Therapy or Cabazitaxel?".
    J Nucl Med. 2025 Apr 30:jnumed.125.270028. doi: 10.2967/jnumed.125.270028.
    >> Share

  97. TRIVIERI MG, Devesa A, Robson PM, Bose S, et al
    Prevalence of Persistent Cardiovascular and Pulmonary Abnormalities on PET/MRI and DECT Imaging in Long COVID Patients.
    J Nucl Med. 2025 Apr 30:jnumed.124.268980. doi: 10.2967/jnumed.124.268980.
    >> Share

  98. PARIHAR AS, Pant N, Heidari P, Fong L, et al
    Approaches to Imaging Immune Activation Using PET.
    J Nucl Med. 2025 Apr 30:jnumed.124.268289. doi: 10.2967/jnumed.124.268289.
    >> Share

  99. SHI B, Zhang Y, Wu S, Xu D, et al
    CD70-Targeted [(18)F]RCCB6 Immuno-PET/CT Imaging in Patients with Nasopharyngeal Carcinoma: A Proof-of-Concept Study.
    J Nucl Med. 2025 Apr 30:jnumed.125.269585. doi: 10.2967/jnumed.125.269585.
    >> Share

  100. FRANCA VELO A, Giantini Larsen A, Humm JL, Zanzonico P, et al
    Determination of the Intralesional Distribution of Theranostic (124)I-Omburtamab Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma.
    J Nucl Med. 2025 Apr 30:jnumed.124.267995. doi: 10.2967/jnumed.124.267995.
    >> Share

  101. DERLIN T, Kleine-Dopke D, Neubert L, Ross TL, et al
    Initial Experience with Dual-Time-Point [(18)F]Flurpiridaz PET/CT for Localization of Parathyroid Adenomas in Primary Hyperparathyroidism.
    J Nucl Med. 2025 Apr 24:jnumed.124.269387. doi: 10.2967/jnumed.124.269387.
    >> Share

  102. ZIMMERMANN R, Beyer T
    Stakeholders of Theranostics: Thomas Beyer Talks with Richard Zimmermann About the Golden Age of Nuclear Medicine.
    J Nucl Med. 2025 Apr 24:jnumed.125.270085. doi: 10.2967/jnumed.125.270085.
    >> Share

  103. UNTERRAINER LM, De Leiris N, Unterrainer M, Delker A, et al
    Evidence-Based Clinical Protocols to Monitor Efficacy of [(177)Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data.
    J Nucl Med. 2025 Apr 24:jnumed.124.269431. doi: 10.2967/jnumed.124.269431.
    >> Share

  104. SMITH CLC, Zwezerijnen GJC, den Hollander ME, Zijlstra JM, et al
    Feasibility of Ultra-Low-Activity (18)F-FDG PET/CT Imaging Using a Long-Axial-Field-of-View PET/CT System.
    J Nucl Med. 2025 Apr 24:jnumed.124.269272. doi: 10.2967/jnumed.124.269272.
    >> Share

  105. THACKERAY JT
    2024 SNMMI Highlights Lecture: Cardiovascular Sciences.
    J Nucl Med. 2025 Apr 24:jnumed.125.269988. doi: 10.2967/jnumed.125.269988.
    >> Share

  106. DAKANALI M, Zigler SS, Schwarz SW, Nickels ML, et al
    FDA Reconsiders Rules Around Radiation Dosimetry for First-in-Human Studies of Investigational PET Radiopharmaceuticals.
    J Nucl Med. 2025 Apr 17:jnumed.125.269885. doi: 10.2967/jnumed.125.269885.
    >> Share

  107. SCHINDLER TH, Bateman TM, Berman DS, Chareonthaitawee P, et al
    FDA Approval of (18)F-Flurpiridaz Is for PET: Stepping into a New Area of Myocardial Perfusion Imaging?
    J Nucl Med. 2025 Apr 17:jnumed.124.269154. doi: 10.2967/jnumed.124.269154.
    >> Share

  108. ALBERTS I, More S, Knapp K, Mei R, et al
    Is Long-Axial-Field-of-View PET/CT Cost-Effective? An International Health-Economic Analysis.
    J Nucl Med. 2025 Apr 17:jnumed.124.269203. doi: 10.2967/jnumed.124.269203.
    >> Share

  109. BRUMBERG J, Schroter N, Blazhenets G, Omrane MA, et al
    [(18)F]Florzolotau PET for the Differential Diagnosis of Parkinsonism in Patients with Suspected 4-Repeat Tauopathies.
    J Nucl Med. 2025 Apr 17:jnumed.124.268956. doi: 10.2967/jnumed.124.268956.
    >> Share

  110. FAROLFI A, Casadei B, Malizia C, Ussia R, et al
    Semiquantitative PET Parameters Refine Prognosis in CAR T-Treated Lymphoma After 1 and 3 Months: A Prospective Single-Center Study.
    J Nucl Med. 2025 Apr 17:jnumed.125.269670. doi: 10.2967/jnumed.125.269670.
    >> Share

  111. HACHEY JS, Viray TD, Matasci M, Ravazza D, et al
    Targeting Extra Domain A of Fibronectin to Improve Noninvasive Detection of Triple-Negative Breast Cancer.
    J Nucl Med. 2025 Apr 17:jnumed.124.268859. doi: 10.2967/jnumed.124.268859.
    >> Share

  112. DE OLIVEIRA TAVEIRA M, Razmaria AA, Schoder H, Yeh R, et al
    Prostate Cancer Recurrence Due to Isolated Testicular Metastases Detected by PSMA PET/CT.
    J Nucl Med. 2025 Apr 10:jnumed.124.269361. doi: 10.2967/jnumed.124.269361.
    >> Share

  113. SARI H, Teimoorisichani M, Viscione M, Mingels C, et al
    Feasibility of an Ultra-Low-Dose PET Scan Protocol with CT-Based and LSO-TX-Based Attenuation Correction Using a Long-Axial-Field-of-View PET/CT Scanner.
    J Nucl Med. 2025 Apr 10:jnumed.124.268380. doi: 10.2967/jnumed.124.268380.
    >> Share

  114. ZHANG Y, Yue J, Yang X, Fei G, et al
    [(68)Ga]Ga-RAYZ-8009: A Peptide PET Tracer for Targeting HCC in Humans.
    J Nucl Med. 2025 Apr 10:jnumed.124.269294. doi: 10.2967/jnumed.124.269294.
    >> Share

  115. HICKS RJ
    Diagnostic Radiopharmaceutical Trial Design: Is It Time to Change Nomenclature?
    J Nucl Med. 2025 Apr 3:jnumed.125.269496. doi: 10.2967/jnumed.125.269496.
    >> Share

  116. BARRY N, Kendrick J, Rowshanfarzad P, Hassan GM, et al
    An External, Independent Validation of an O-(2-[(18)F]Fluoroethyl)-l-Tyrosine PET Automatic Segmentation Network on a Single-Center, Prospective Dataset of Patients with Glioblastoma.
    J Nucl Med. 2025 Apr 3:jnumed.124.268925. doi: 10.2967/jnumed.124.268925.
    >> Share

  117. LEE Y, Nguyen TD, Du Y, Coughlin JM, et al
    Validating the Utility of Supervised Clustering Algorithm for Precise [(11)C]DPA-713 PET Brain Image Quantification.
    J Nucl Med. 2025 Apr 3:jnumed.124.268519. doi: 10.2967/jnumed.124.268519.
    >> Share

  118. SCHOLTISSEK H, Reitsam NG, Dierks A, Kroncke T, et al
    Noninvasive Characterization of Hepatic Lesions by Means of Glypican-3-Directed PET/CT.
    J Nucl Med. 2025 Apr 3:jnumed.124.269290. doi: 10.2967/jnumed.124.269290.
    >> Share

  119. GIORGIO J, Soleimani-Meigooni DN, Janabi M, Baker SL, et al
    Imaging Synaptic Density in Aging and Alzheimer Disease with [(18)F]SynVesT-1.
    J Nucl Med. 2025;66:620-625.
    >> Share

  120. LI X, Zhang Y, Mixdorf JC, Wu Q, et al
    Development and Preclinical Evaluation of [(64)Cu]Cu-NOTA-ABDB6: A CD70 and Albumin Dual-Binding Tracer with Improved Pharmacokinetics.
    J Nucl Med. 2025;66:552-558.
    >> Share

  121. LI S, Abdelhafez YG, Nardo L, Cherry SR, et al
    Total-Body Parametric Imaging Using Relative Patlak Plot.
    J Nucl Med. 2025;66:654-661.
    >> Share

  122. MILLER RJH, Kavanagh P, Lemley M, Liang JX, et al
    Artificial Intelligence-Enhanced Perfusion Scoring Improves the Diagnostic Accuracy of Myocardial Perfusion Imaging.
    J Nucl Med. 2025;66:648-653.
    >> Share

  123. UDOVICICH C, Bressel M, Manji J, Ali M, et al
    PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL Study.
    J Nucl Med. 2025;66:531-536.
    >> Share

    March 2025
  124. AL-IBRAHEEM A, Scott AM, Abdlkadir AS, Vrachimis A, et al
    Consensus Nomenclature for Radionuclide Therapy: Initial Recommendations from Nuclear Medicine Global Initiative.
    J Nucl Med. 2025 Mar 27:jnumed.124.269215. doi: 10.2967/jnumed.124.269215.
    >> Share

  125. MECKEL M, Ehrenberg S, Schmidt T, Ritt P, et al
    Reduced Renal Uptake of Various Radiopharmaceuticals with Sodium Paraaminohippurate Coadministration in a Rat Model.
    J Nucl Med. 2025 Mar 27:jnumed.124.268411. doi: 10.2967/jnumed.124.268411.
    >> Share

  126. SABAHI Z, Nguyen A, Wong K, Li S, et al
    Diagnostic Potential of (68)Ga-NeoB PET/CT with Estrogen Receptor- and Progesterone Receptor-Positive Breast Cancer Undergoing Staging or Restaging for Metastatic Disease.
    J Nucl Med. 2025 Mar 27:jnumed.124.268896. doi: 10.2967/jnumed.124.268896.
    >> Share

  127. CHEN DC, Buteau JP, Emmett L, Alipour R, et al
    Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [(68)Ga]Ga-PSMA-11 PET/CT in the proPSMA Study.
    J Nucl Med. 2025 Mar 27:jnumed.124.268901. doi: 10.2967/jnumed.124.268901.
    >> Share

  128. HERR FL, Dascalescu C, Fabritius MP, Sheikh GT, et al
    PET- and CT-Based Imaging Criteria for Response Assessment of Gastroenteropancreatic Neuroendocrine Tumors Under Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Mar 27:jnumed.124.268621. doi: 10.2967/jnumed.124.268621.
    >> Share

  129. HINDIE E, Patel RB
    Synergy Between Radiopharmaceutical Therapy and Immune Response: Deciphering the Underpinning Mechanisms for Future Actions.
    J Nucl Med. 2025 Mar 27:jnumed.125.269644. doi: 10.2967/jnumed.125.269644.
    >> Share

  130. SUN H, Cheng D, Du X, Sun C, et al
    A Rare Influenza B Virus-Associated Cerebellitis Detected by (18)F-FDG PET/CT Imaging.
    J Nucl Med. 2025 Mar 27:jnumed.125.269548. doi: 10.2967/jnumed.125.269548.
    >> Share

  131. TANG W, Qi L, Chen M, Zhang Y, et al
    Additive Value of [(68)Ga]Ga-RM26 PET/CT to [(68)Ga]Ga-PSMA-617 PET/CT in Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective, Single-Center, Phase II Study.
    J Nucl Med. 2025 Mar 20:jnumed.124.269189. doi: 10.2967/jnumed.124.269189.
    >> Share

  132. BOELLAARD R, Zwezerijnen GJC, Buvat I, Champion L, et al
    Measuring Total Metabolic Tumor Volume from (18)F-FDG PET: A Reality Check.
    J Nucl Med. 2025 Mar 13:jnumed.124.269271. doi: 10.2967/jnumed.124.269271.
    >> Share

  133. HAUSMANN P, Zschaeck S, Furth C, Nikulin P, et al
    Tumor Asphericity in FDG PET Is an Independent Prognostic Parameter Improving Risk Stratification in Patients with Head and Neck Squamous Cell Carcinoma.
    J Nucl Med. 2025 Mar 13:jnumed.124.268972. doi: 10.2967/jnumed.124.268972.
    >> Share

  134. CONSTANTINO CS, Oliveira FPM, Machado M, Vinga S, et al
    The Use of Maximum-Intensity Projections and Deep Learning Adds Value to the Fully Automatic Segmentation of Lesions Avid for [(18)F]FDG and [(68)Ga]Ga-PSMA in PET/CT.
    J Nucl Med. 2025 Mar 13:jnumed.124.269067. doi: 10.2967/jnumed.124.269067.
    >> Share

  135. REED MB, Murgas M, Lanzenberger R, Hahn A, et al
    The Value of Functional PET in Quantifying Neurotransmitter Dynamics.
    J Nucl Med. 2025 Mar 13:jnumed.124.269238. doi: 10.2967/jnumed.124.269238.
    >> Share

  136. TUNALI I, Wang J, Arora AK, Kim MJ, et al
    Development and Validation of a (18)F-Flortaucipir PET Visual Stratification Method.
    J Nucl Med. 2025 Mar 13:jnumed.124.268700. doi: 10.2967/jnumed.124.268700.
    >> Share

  137. MORRIS ED, Emvalomenos GM, Hoye J, Meikle SR, et al
    Reply to "The Value of Functional PET in Quantifying Neurotransmitter Dynamics".
    J Nucl Med. 2025 Mar 13:jnumed.125.269473. doi: 10.2967/jnumed.125.269473.
    >> Share

  138. PARIHAR AS, Vaz S, Sutcliffe S, Pant N, et al
    (18)F-Fluoroestradiol PET/CT for Predicting Benefit from Endocrine Therapy in Patients with Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Metaanalysis.
    J Nucl Med. 2025 Mar 13:jnumed.124.269163. doi: 10.2967/jnumed.124.269163.
    >> Share

  139. MORAITIS A, Prochnow A, Poeppel TD, Schmitz J, et al
    Tumor Dose-Response Relationship of [(131)I]MIBG Therapy in Patients with Neural Crest Tumors by Means of [(124)I]MIBG PET.
    J Nucl Med. 2025 Mar 13:jnumed.124.269377. doi: 10.2967/jnumed.124.269377.
    >> Share

  140. BERNER K, Hernes E, Kvassheim M, Revheim ME, et al
    First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted (212)Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Mar 13:jnumed.124.269299. doi: 10.2967/jnumed.124.269299.
    >> Share

  141. LIU S, Pan Q, Zhang H, Peng L, et al
    Differences in Fibroinflammatory Activity Shown on (68)Ga-FAPI-04 and (18)F-FDG PET/CT in the Two Subtypes of IgG4-Related Disease.
    J Nucl Med. 2025 Mar 6:jnumed.124.268943. doi: 10.2967/jnumed.124.268943.
    >> Share

  142. JUWEID ME, Al-Leimon O, Al-Qasem SF, Aljarah I, et al
    Self-Citation Among Highly Cited Nuclear Medicine and Medical Imaging Researchers.
    J Nucl Med. 2025 Mar 6:jnumed.124.269357. doi: 10.2967/jnumed.124.269357.
    >> Share

  143. METSER U, Lukovic J, Mesci A, MacCrostie P, et al
    [(18)F]-FDG PET/CT in the Initial Staging of Squamous Cell Cancer of the Anal Canal: Results of a Prospective Multicenter Registry.
    J Nucl Med. 2025 Mar 6:jnumed.124.269289. doi: 10.2967/jnumed.124.269289.
    >> Share

  144. FOXTON C, Waldron B, Veggerby Gronlund R, Simon JJ, et al
    Preclinical Evaluation of (177)Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy.
    J Nucl Med. 2025 Mar 6:jnumed.124.268508. doi: 10.2967/jnumed.124.268508.
    >> Share

  145. KNUUTI J, Kobylecka M, Krajewski S, Steczek L, et al
    Biodistribution, Safety Profile, and Radiation Dosimetry of [(18)F]SYN2, a PET Cardiac Perfusion Tracer, in Healthy Subjects.
    J Nucl Med. 2025 Mar 6:jnumed.124.268872. doi: 10.2967/jnumed.124.268872.
    >> Share

  146. IMBER BS, Yu KKH, Abida W, Pike LRG, et al
    Symptomatic Prostate-Specific Membrane Antigen PET-Positive Radionecrosis After Multimodality Brain Metastasis-Directed Treatment Including [(177)Lu]Lu-PSMA-617.
    J Nucl Med. 2025 Mar 6:jnumed.124.269175. doi: 10.2967/jnumed.124.269175.
    >> Share

  147. WANG R, Wang J, Xiang J, Sui H, et al
    Comparison of [(68)Ga]Ga-Fibroblast Activation Protein Inhibitor-04 and [(18)F]FDG PET Imaging for Solitary Fibrous Tumor and Preliminary Application of FAP-Targeted Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Mar 6:jnumed.124.268258. doi: 10.2967/jnumed.124.268258.
    >> Share

  148. KURKOWSKA S, Brosch-Lenz J, Dewaraja YK, Frey E, et al
    An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 4: Impact of Fitting Functions in Estimated Absorbed Doses.
    J Nucl Med. 2025;66:441-448.
    >> Share

  149. BODEI L, Cremonesi M, Ferrari M, Mittra ES, et al
    Dosimetry of [(177)Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial.
    J Nucl Med. 2025;66:449-456.
    >> Share

  150. FU JF, Juttukonda MR, Garimella A, Salvatore AN, et al
    [(18)F]MK-6240 Radioligand Delivery Indices as Surrogates of Cerebral Perfusion: Bias and Correlation Against [(15)O]Water.
    J Nucl Med. 2025;66:410-417.
    >> Share

  151. AHMAD AA, Ghim M, Kukreja G, Neishabouri A, et al
    Collagen Hybridizing Peptide-Based Radiotracers for Molecular Imaging of Collagen Turnover in Pulmonary Fibrosis.
    J Nucl Med. 2025;66:425-433.
    >> Share

  152. GILLETT D, Senanayake R, MacFarlane J, Bashari W, et al
    A Phase I/IIa Clinical Trial to Evaluate Safety and Adrenal Uptake of Para-Chloro-2-[(18)F]Fluoroethyletomidate in Healthy Volunteers and Patients with Primary Aldosteronism.
    J Nucl Med. 2025;66:434-440.
    >> Share

  153. MARQUIS H, Schmidtlein CR, de Nijs R, Minguez Gabina P, et al
    MIRD Pamphlet No. 32: A MIRD Recovery Coefficient Model for Resolution Characterization and Shape-Specific Partial-Volume Correction.
    J Nucl Med. 2025;66:457-465.
    >> Share

    February 2025
  154. MURTHY V, Ludwig V, Gafita A, Hope TA, et al
    The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Feb 27:jnumed.124.268818. doi: 10.2967/jnumed.124.268818.
    >> Share

  155. MENCH A, Winters C, Mittra E, Szidonya L, et al
    Navigating Radiation Safety After Radiopharmaceutical Therapies: Proposed Workflow and Essential Guidelines for Nonspecialists.
    J Nucl Med. 2025 Feb 27:jnumed.124.268522. doi: 10.2967/jnumed.124.268522.
    >> Share

  156. WANG J, Lan X, Shi H, Li S, et al
    A Brief Report on the Results of the 2024 National Survey of Nuclear Medicine Conducted by the Chinese Society of Nuclear Medicine.
    J Nucl Med. 2025 Feb 27:jnumed.124.269044. doi: 10.2967/jnumed.124.269044.
    >> Share

  157. CONSTANZO J, Parach A, David T, Karam J, et al
    MHC-I-Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Feb 27:jnumed.124.268857. doi: 10.2967/jnumed.124.268857.
    >> Share

  158. TURCO F, Gillessen S, Herrmann K, Paone G, et al
    Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Feb 27:jnumed.124.267730. doi: 10.2967/jnumed.124.267730.
    >> Share

  159. VERA P, Giraud P, Hapdey S, Gouel P, et al
    Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer.
    J Nucl Med. 2025 Feb 27:jnumed.124.268499. doi: 10.2967/jnumed.124.268499.
    >> Share

  160. GAJECKI L, Lebedeva IV, Liao YR, Ambriz D, et al
    IL13Ralpha2-Targeting Antibodies for Immuno-PET in Solid Malignancies.
    J Nucl Med. 2025 Feb 20:jnumed.124.268762. doi: 10.2967/jnumed.124.268762.
    >> Share

  161. CHEVALEYRE C, Zimmermann L, Specklin S, Kereselidze D, et al
    PET Imaging of PD-L1 Occupancy for Preclinical Assessment of the Efficacy of Combined Anti-PD-L1 Immunotherapy and Targeted Therapy.
    J Nucl Med. 2025 Feb 20:jnumed.124.268586. doi: 10.2967/jnumed.124.268586.
    >> Share

  162. VIERING O, Holzleitner N, Claus R, Amerein A, et al
    CCK(2) Receptor Ligand [(68)Ga]Ga-DOTA-CCK-66 PET/CT Outperforms [(68)Ga]Ga-DOTATOC PET/CT in a Patient with Small Cell Lung Cancer.
    J Nucl Med. 2025 Feb 20:jnumed.124.269201. doi: 10.2967/jnumed.124.269201.
    >> Share

  163. VAN RIJSEWIJK ND, Lanz P, Wouthuyzen-Bakker M, Glaudemans AWJM, et al
    Evaluating Bone Healing with [(18)F]NaF PET/CT During Bone Segment Transport in Femoral Fracture Treatment.
    J Nucl Med. 2025 Feb 20:jnumed.124.268913. doi: 10.2967/jnumed.124.268913.
    >> Share

  164. BABEKER H, Njotu FN, Pougoue Ketchemen J, Monzer A, et al
    (225)Ac/(89)Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4-Positive Triple-Negative Breast Cancer.
    J Nucl Med. 2025 Feb 20:jnumed.124.268387. doi: 10.2967/jnumed.124.268387.
    >> Share

  165. SANTORO-FERNANDES V, Schott B, Weisman AJ, Lokre O, et al
    Full-Body Tumor Response Heterogeneity of Metastatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Feb 13:jnumed.124.267809. doi: 10.2967/jnumed.124.267809.
    >> Share

  166. MOSTAFAPOUR S, van Sluis J, Lammertsma AA, Tsoumpas C, et al
    (176)Lu Radiation Dose of Long-Axial Field of View PET Scanners.
    J Nucl Med. 2025 Feb 13:jnumed.124.269187. doi: 10.2967/jnumed.124.269187.
    >> Share

  167. YU S, Yang Z, Ding Z, Jia Y, et al
    (68)Ga-FAPI-04 PET/CT Imaging for Assessing Renal Tubulointerstitial Fibrosis in Lupus Nephritis.
    J Nucl Med. 2025 Feb 13:jnumed.124.268643. doi: 10.2967/jnumed.124.268643.
    >> Share

  168. SUN Y, Hao Z, Gao H, Yang G, et al
    [(99m)Tc]Tc-MY6349 Probe for Trop2-Targeted SPECT Imaging: From Preclinical to Pilot Clinical Study.
    J Nucl Med. 2025 Feb 13:jnumed.124.268564. doi: 10.2967/jnumed.124.268564.
    >> Share

  169. YUSUFALY T, Roncali E, Brosch-Lenz J, Uribe C, et al
    Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories.
    J Nucl Med. 2025 Feb 13:jnumed.124.267927. doi: 10.2967/jnumed.124.267927.
    >> Share

  170. BABICH J, Kostakoglu L
    New Approaches in Radiopharmaceutical Development: John Babich Talks with Lale Kostakoglu About Current and Coming Trends in Diagnostics and Therapeutics.
    J Nucl Med. 2025 Feb 13:jnumed.125.269492. doi: 10.2967/jnumed.125.269492.
    >> Share

  171. SUN L, Sun Y, Zuo K, Fan L, et al
    Pilot Study of Nectin-4-Targeted PET Imaging Agent (68)Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human.
    J Nucl Med. 2025 Feb 13:jnumed.124.269024. doi: 10.2967/jnumed.124.269024.
    >> Share

  172. CZERNIN J, Bodei L, Modlin I, Calais J, et al
    Reflections on the Demand for PSMA- and SSTR-Targeted Radiopharmaceutical Therapies: Why We Were Wrong (and Why We Will Be Right Eventually).
    J Nucl Med. 2025 Feb 6:jnumed.124.269401. doi: 10.2967/jnumed.124.269401.
    >> Share

  173. LASSEN ML, Kertesz H, Rausch I, Panin V, et al
    Positron Range Correction Helps Enhance the Image Quality of Cardiac (82)Rb PET/CT.
    J Nucl Med. 2025 Feb 6:jnumed.124.267855. doi: 10.2967/jnumed.124.267855.
    >> Share

  174. MORAITIS A, Kahl T, Kandziora J, Jentzen W, et al
    Evaluation of Surgical Margins with Intraoperative PSMA PET/CT and Their Prognostic Value in Radical Prostatectomy.
    J Nucl Med. 2025 Feb 6:jnumed.124.268719. doi: 10.2967/jnumed.124.268719.
    >> Share

  175. DERLIN T, Widjaja L, Harke NN, Czerner C, et al
    (99m)Tc-MIP-1404 SPECT/CT Companion Diagnostic for (177)Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Feb 6:jnumed.124.269319. doi: 10.2967/jnumed.124.269319.
    >> Share

  176. VAN DER GAAG S, Vis AN, Bartelink IH, Koppes JCC, et al
    Exploring the Flare Phenomenon in Patients with Castration-Resistant Prostate Cancer: Enzalutamide-Induced PSMA Upregulation Observed on PSMA PET.
    J Nucl Med. 2025 Feb 6:jnumed.124.268340. doi: 10.2967/jnumed.124.268340.
    >> Share

  177. GHEYSENS O, Pelletier-Galarneau M, Treglia G, Israel O, et al
    Summary: EANM/SNMMI Release Joint Guideline/Procedure Standard for [(18)F]FDG Hybrid PET Use in Infection and Inflammation in Adults, Version 2.0.
    J Nucl Med. 2025 Feb 6:jnumed.125.269538. doi: 10.2967/jnumed.125.269538.
    >> Share

  178. LINDENBERG L, Hope TA, Lin FI, Rowe SP, et al
    Safety, Dosimetry, and Feasibility of [(68)Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer.
    J Nucl Med. 2025 Feb 6:jnumed.124.268318. doi: 10.2967/jnumed.124.268318.
    >> Share

  179. OGATA A, Ikenuma H, Yasuno F, Nihashi T, et al
    First-in-Human Study of [(11)C]NCGG401 for Imaging Colony-Stimulating Factor 1 Receptors in the Brain.
    J Nucl Med. 2025;66:302-308.
    >> Share

  180. OLAFSON E, Tonietto M, Klein G, Teng E, et al
    In Vivo Head-to-Head Comparison of [(18)F]GTP1 with [(18)F]MK-6240 and [(18)F]PI-2620 in Alzheimer Disease.
    J Nucl Med. 2025;66:277-285.
    >> Share

  181. SONG Y, Lee JH, Kim HK, Lee JH, et al
    Longitudinal Trajectory of Dopamine and Serotonin Transporters in Parkinson Disease.
    J Nucl Med. 2025;66:286-292.
    >> Share

  182. OH M, Brumberg J, Sossi V, Varrone A, et al
    Preserved Serotonin Transporter Availability in Parkinson Disease Measured with Either [(11)C]MADAM or [(11)C]DASB: A Study Including 2 Separate Cohorts of Nondepressed Patients.
    J Nucl Med. 2025;66:309-314.
    >> Share

    January 2025
  183. WANG X, Dong Y, Zhang S
    China's Innovations in Nuclear Medicine: Global Insights into Clinical Advancements and Impact.
    J Nucl Med. 2025 Jan 30:jnumed.124.269185. doi: 10.2967/jnumed.124.269185.
    >> Share

  184. MIEDERER I, Buchholz HG, Rademacher L, Eckart C, et al
    Dopaminergic Mechanisms of Cognitive Flexibility: An [(18)F]Fallypride PET Study.
    J Nucl Med. 2025 Jan 30:jnumed.124.268317. doi: 10.2967/jnumed.124.268317.
    >> Share

  185. ULANER GA, Lewis J, Landgren O
    CD38-Targeted (89)Zr-DFO-Daratumumab PET of Myeloma: Immuno-PET Impacting Clinical Care.
    J Nucl Med. 2025 Jan 30:jnumed.124.269393. doi: 10.2967/jnumed.124.269393.
    >> Share

  186. STRIGARI L, Schwarz J, Bradshaw T, Brosch-Lenz J, et al
    Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Ethical, Regulatory, and Socioeconomic Dimensions of Theranostic Digital Twins.
    J Nucl Med. 2025 Jan 23:jnumed.124.268186. doi: 10.2967/jnumed.124.268186.
    >> Share

  187. VAN GEEL JJL, Moustaquim J, Boers J, Elias SG, et al
    Intrapatient 16alpha-[(18)F]Fluoro-17beta-Estradiol PET Heterogeneity as a Prognostic Factor for Endocrine Therapy Response and Survival in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
    J Nucl Med. 2025 Jan 23:jnumed.124.268984. doi: 10.2967/jnumed.124.268984.
    >> Share

  188. WANG R, Huang M, Wang W, Li M, et al
    Preclinical Evaluation of (68)Ga/(177)Lu-Labeled FAP-Targeted Peptide for Tumor Radiopharmaceutical Imaging and Therapy.
    J Nucl Med. 2025 Jan 23:jnumed.124.268689. doi: 10.2967/jnumed.124.268689.
    >> Share

  189. LAWAL IO, Mushtaq A, Jani AB, Rupji M, et al
    Diuresis During (18)F-Flotufolastat (rhPSMA-7.3) PET/CT Improves Recurrence Detection After Prostatectomy: A Prospective Phase II Trial.
    J Nucl Med. 2025 Jan 23:jnumed.124.268574. doi: 10.2967/jnumed.124.268574.
    >> Share

  190. YAN X, Noergaard M, Morse CL, Liow JS, et al
    PET Quantification in Healthy Humans of Cyclooxygenase-2, a Potential Biomarker of Neuroinflammation.
    J Nucl Med. 2025 Jan 23:jnumed.124.268525. doi: 10.2967/jnumed.124.268525.
    >> Share

  191. VEIT-HAIBACH P, Herrmann K, Zimmermann R, Hustinx R, et al
    Green Nuclear Medicine and Radiotheranostics.
    J Nucl Med. 2025 Jan 23:jnumed.124.268928. doi: 10.2967/jnumed.124.268928.
    >> Share

  192. BAILEY DL, Willowson KP, O'Keefe G, Goodman S, et al
    A Method for Validating PET and SPECT Cameras for Quantitative Clinical Imaging Trials Using Novel Radionuclides.
    J Nucl Med. 2025 Jan 16:jnumed.124.268578. doi: 10.2967/jnumed.124.268578.
    >> Share

  193. ENKE JS, Reitsam NG, Dintner S, Liesche-Starnecker F, et al
    Comprehensive Characterization via Molecular Imaging, Longitudinal Multisite Sampling, and Autoptic Work-up in Advanced Small Cell Lung Cancer Undergoing SSTR-Directed Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Jan 16:jnumed.124.268513. doi: 10.2967/jnumed.124.268513.
    >> Share

  194. BARBRY F, Chevalier B, Beron A, Lion G, et al
    Redifferentiation of a RET-Fusion, Radioiodine-Refractory, Differentiated Thyroid Cancer with Selpercatinib: Flip-Flop Between [(18)F]FDG PET/CT and (131)I Posttreatment Scanning.
    J Nucl Med. 2025 Jan 16:jnumed.124.268539. doi: 10.2967/jnumed.124.268539.
    >> Share

  195. CERIANI L, Milan L, Pirosa MC, Martelli M, et al
    PET-Based Risk Stratification in Primary Mediastinal B-Cell Lymphoma: A Comparative Analysis of Different Segmentation Methods in the IELSG37 Trial Patient Cohort.
    J Nucl Med. 2025 Jan 16:jnumed.124.268874. doi: 10.2967/jnumed.124.268874.
    >> Share

  196. PRASAD N, Harris E, DeFilippis EM, Sayer G, et al
    PET/CT with Myocardial Blood Flow Assessment Is Prognostic of Cardiac Allograft Vasculopathy Progression and Clinical Outcomes.
    J Nucl Med. 2025 Jan 16:jnumed.124.268713. doi: 10.2967/jnumed.124.268713.
    >> Share

  197. GAO M, Daube-Witherspoon ME, Karp JS, Surti S, et al
    Total-Body PET System Designs with Axial and Transverse Gaps: A Study of Lesion Quantification and Detectability.
    J Nucl Med. 2025 Jan 16:jnumed.124.267769. doi: 10.2967/jnumed.124.267769.
    >> Share

  198. LANGEN KJ, Stoffels G, Filss CP, Kocher M, et al
    Borderline Findings in O-(2-[(18)F]-Fluoroethyl)-l-Tyrosine PET of Patients with Suspected Glioma Relapse: Role in Clinical Practice.
    J Nucl Med. 2025 Jan 16:jnumed.124.268768. doi: 10.2967/jnumed.124.268768.
    >> Share

  199. RAMOS-TORRES KM, Conti S, Zhou YP, Tiss A, et al
    Imaging Demyelinated Axons After Spinal Cord Injuries with PET Tracer [(18)F]3F4AP.
    J Nucl Med. 2025 Jan 16:jnumed.124.268242. doi: 10.2967/jnumed.124.268242.
    >> Share

  200. VON GUGGENBERG E, di Santo G, Uprimny C, Bayerschmidt S, et al
    Safety, Biodistribution, and Radiation Dosimetry of the (68)Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.
    J Nucl Med. 2025 Jan 16:jnumed.124.268877. doi: 10.2967/jnumed.124.268877.
    >> Share

  201. VRAKA C, Homolya M, Ozer O, Spittler A, et al
    RadioFlow Cytometry Reveals That [(18)F]FDG Uptake in K-RAS Lung Cancer Is Driven by Immune Cells: An Analysis on a Single-Cell Level.
    J Nucl Med. 2025 Jan 16:jnumed.124.268799. doi: 10.2967/jnumed.124.268799.
    >> Share

  202. RABINOVICI GD, Knopman DS, Arbizu J, Benzinger TLS, et al
    Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.
    J Nucl Med. 2025 Jan 8:jnumed.124.268756. doi: 10.2967/jnumed.124.268756.
    >> Share

  203. MADSEN C, Fuglo D, Pedersen M, Broholm R, et al
    Prospective Head-to-Head Comparison of (18)F-PSMA PET/CT and (18)F-NaF PET/CT for Assessing Bone Metastases in 160 Patients with Newly Diagnosed High-Risk Prostate Cancer.
    J Nucl Med. 2025 Jan 8:jnumed.124.268275. doi: 10.2967/jnumed.124.268275.
    >> Share

  204. MILLER SR, Gonzalez RT, Jackson WC, Caram MEV, et al
    Rates of PSMA PET Staging and Positivity in Newly Diagnosed Prostate Cancer in a National Health Care System.
    J Nucl Med. 2025;66:75-83.
    >> Share

  205. UNTERRAINER LM, Hope TA, Fendler WP, Grogan T, et al
    Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study.
    J Nucl Med. 2025;66:54-60.
    >> Share

  206. MILLER RJH, Patel KK, Kwiecinski J, Slipczuk L, et al
    Nuclear Cardiology Surrogate Biomarkers in Clinical Trials.
    J Nucl Med. 2025;66:4-11.
    >> Share

  207. HOU P, Chen H, Liang S, Guo W, et al
    Targeting Fibroblast Activation Protein for Molecular Imaging of Fibrotic Remodeling in Pulmonary Arterial Hypertension.
    J Nucl Med. 2025;66:98-103.
    >> Share

  208. BARTEL T
    2024 SNMMI Highlights Lecture: General Clinical Specialties.
    J Nucl Med. 2025;66:158-161.
    >> Share

  209. MICHNO M, Schmitz J, Foerges AL, Beer S, et al
    Effect of Acute Hypoxia Exposure on the Availability of A(1) Adenosine Receptors and Perfusion in the Human Brain.
    J Nucl Med. 2025;66:142-149.
    >> Share

  210. OMIDVARI N, Shanina E, Leung EK, Sun X, et al
    Quantitative Accuracy Assessment of the NeuroEXPLORER for Diverse Imaging Applications: Moving Beyond Standard Evaluations.
    J Nucl Med. 2025;66:150-157.
    >> Share

  211. PARIHAR AS, Mhlanga JC, Royal HD, Siegel BA, et al
    Comparability of Quantifying Relative Lung Ventilation with Inhaled (99m)Tc-Technegas and (133)Xe in Patients Undergoing Evaluation for Lung Transplantation.
    J Nucl Med. 2025;66:104-109.
    >> Share

  212. GHAZANFARI N, Liow JS, Kim MJ, Cureton R, et al
    [(11)C]PS13 Demonstrates Pharmacologically Selective and Substantial Binding to Cyclooxygenase-1 in the Human Brain.
    J Nucl Med. 2025;66:117-122.
    >> Share

  213. SCHWEIGER L, Maurer T, Simon R, Horn T, et al
    Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery.
    J Nucl Med. 2025;66:67-72.
    >> Share

  214. GOTO T, Kikuchi S, Sakurai Y, Tsuruta Y, et al
    Cardiac Presynaptic Sympathetic Nervous Function Evaluated by Cardiac PET in Patients with Chronotropic Incompetence Without Heart Failure.
    J Nucl Med. 2025 Jan 2:jnumed.124.268638. doi: 10.2967/jnumed.124.268638.
    >> Share

  215. EMMETT L
    SPECT Deserves RESPECT: The Potential of SPECT/CT to Optimize Patient Outcomes with Theranostics Therapy.
    J Nucl Med. 2025 Jan 2:jnumed.124.268325. doi: 10.2967/jnumed.124.268325.
    >> Share

    December 2024
  216. CHENG K, Ge L, Song M, Li W, et al
    Preclinical Evaluation and Pilot Clinical Study of CD137 PET Radiotracer for Noninvasive Monitoring Early Responses of Immunotherapy.
    J Nucl Med. 2024 Dec 12:jnumed.124.268068. doi: 10.2967/jnumed.124.268068.
    >> Share

  217. ROUSSEAU JA, Maier M, Ait-Mohand S, Dumulon-Perreault V, et al
    Antibody-Based PET Imaging of Misfolded Superoxide Dismutase 1 in an Amyotrophic Lateral Sclerosis Mouse Model.
    J Nucl Med. 2024 Dec 12:jnumed.124.268343. doi: 10.2967/jnumed.124.268343.
    >> Share

  218. WEEKS JK, Pantel AR, Gitto SB, Liu F, et al
    [(18)F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [(18)F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status.
    J Nucl Med. 2024 Dec 5:jnumed.124.267627. doi: 10.2967/jnumed.124.267627.
    >> Share

  219. VAN DER WEIJDEN CWJ, Ahmed AKMA, van der Hoorn A, Zhu J, et al
    Myelin Imaging of the Spinal Cord in Animal Models and Patients with Multiple Sclerosis Using [(11)C]MeDAS PET: A Translational Study.
    J Nucl Med. 2024 Dec 5:jnumed.123.266896. doi: 10.2967/jnumed.123.266896.
    >> Share

  220. CUTLER CS
    A Banner Year for Nuclear Medicine, Molecular Imaging, and Theranostics.
    J Nucl Med. 2024;65:7A-8A.
    >> Share

  221. VERGOTE VKJ, Verhoef G, Janssens A, Woei-A-Jin FJSH, et al
    International Metabolic Prognostic Index Is Superior to Other Metabolic Tumor Volume-Based Prognostication Methods in a Real-Life Cohort of Diffuse Large B-Cell Lymphoma.
    J Nucl Med. 2024;65:1876-1883.
    >> Share

  222. MICHALSKI K, Kosmala A, Hartrampf PE, Heinrich M, et al
    [(18)F]FDG and [(68)Ga]Ga-FAPI-04-Directed Imaging for Outcome Prediction in Patients with High-Grade Neuroendocrine Neoplasms.
    J Nucl Med. 2024;65:1899-1903.
    >> Share

    November 2024
  223. HOPE TA, Calais J, Goenka AH, Haberkorn U, et al
    SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET.
    J Nucl Med. 2024 Nov 21:jnumed.124.269002. doi: 10.2967/jnumed.124.269002.
    >> Share

  224. JACENE H, Czernin J
    Solving Challenging Puzzles: Heather Jacene Talks with Johannes Czernin About Leadership in Clinical Nuclear Medicine and the SNMMI.
    J Nucl Med. 2024 Nov 21:jnumed.124.269029. doi: 10.2967/jnumed.124.269029.
    >> Share

  225. ERMIS E, Bachmann N, Lutz K, Pyka T, et al
    Meningioma Revisited: Should Whole-Body Staging with [(68)Ga]Ga-DOTATOC PET/CT of High-Grade Meningiomas Become Standard Practice?
    J Nucl Med. 2024 Nov 21:jnumed.124.267934. doi: 10.2967/jnumed.124.267934.
    >> Share

  226. DEMIRCI RA, Ghodsi A, Gulati R, Behnia S, et al
    PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received (177)Lu-PSMA-617: Importance of (18)F-FDG-Avid Discordant Findings.
    J Nucl Med. 2024 Nov 14:jnumed.124.268167. doi: 10.2967/jnumed.124.268167.
    >> Share

  227. WENZEL M, Koll F, Hoeh B, Humke C, et al
    Real-World Comparison of Cabazitaxel Versus (177)Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Nov 14:jnumed.124.268807. doi: 10.2967/jnumed.124.268807.
    >> Share

  228. COLLIJ LE, Bischof GN, Altomare D, Bader I, et al
    Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study.
    J Nucl Med. 2024 Nov 14:jnumed.124.268119. doi: 10.2967/jnumed.124.268119.
    >> Share

  229. LOU K, Wang J, He H, Wang Y, et al
    Value of [(68)Ga]Ga-NYM046 PET/CT, in Comparison with (18)F-FDG PET/CT, for Diagnosis of Clear Cell Renal Cell Carcinoma.
    J Nucl Med. 2024 Nov 14:jnumed.124.267527. doi: 10.2967/jnumed.124.267527.
    >> Share

  230. HUANG W, Cao M, Wu Y, Zhang Y, et al
    Immuno-PET/CT Imaging of Trop2 with [(18)F]AlF-RESCA-T4 Differentiates Lung Cancer from Inflammation.
    J Nucl Med. 2024 Nov 14:jnumed.124.268751. doi: 10.2967/jnumed.124.268751.
    >> Share

  231. DEMIRCI RA, Gulati R, Hawley JE, Yezefski T, et al
    SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving (177)Lu-PSMA-617.
    J Nucl Med. 2024 Nov 7:jnumed.124.267665. doi: 10.2967/jnumed.124.267665.
    >> Share

  232. ZHANG H, Ren C, Liu Y, Yan X, et al
    Performance Characteristics of a New Generation 148-cm Axial Field-of-View uMI Panorama GS PET/CT System with Extended NEMA NU 2-2018 and EARL Standards.
    J Nucl Med. 2024 Nov 7:jnumed.124.267963. doi: 10.2967/jnumed.124.267963.
    >> Share

  233. ZHOU X, Wu Q, Zhai W, Zhang Y, et al
    CD70-Targeted Immuno-PET/CT Imaging of Clear Cell Renal Cell Carcinoma: A Translational Study.
    J Nucl Med. 2024 Nov 7:jnumed.124.268509. doi: 10.2967/jnumed.124.268509.
    >> Share

  234. KONIAR H, Wharton L, Ingham A, Morales Oliver AP, et al
    Preclinical Evaluation of (226)Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy.
    J Nucl Med. 2024;65:1762-1768.
    >> Share

    October 2024
  235. SONNI I, Weiner AB, Doddipalli S, Deol M, et al
    Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and Multiparametric MRI.
    J Nucl Med. 2024 Oct 30:jnumed.124.268443. doi: 10.2967/jnumed.124.268443.
    >> Share

  236. YOUNG AJ, Pantel AR, Kiani M, Doot RK, et al
    Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted (18)F-Fluorthanatrace PET in Breast Cancer.
    J Nucl Med. 2024 Oct 30:jnumed.124.268254. doi: 10.2967/jnumed.124.268254.
    >> Share

  237. HUANG RR, Zuo C, Mona CE, Holzgreve A, et al
    FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study.
    J Nucl Med. 2024 Oct 30:jnumed.124.268037. doi: 10.2967/jnumed.124.268037.
    >> Share

  238. SWIHA M, Pathmanandavel S, Papa N, Sabahi Z, et al
    Comparison of Posttherapy 4- and 24-Hour [(177)Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Oct 30:jnumed.124.267606. doi: 10.2967/jnumed.124.267606.
    >> Share

  239. HELISCH A, Kratochwil C, Kleist C, Kramer S, et al
    Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with (213)Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors.
    J Nucl Med. 2024 Oct 30:jnumed.124.268386. doi: 10.2967/jnumed.124.268386.
    >> Share

  240. WANG R, Kang W, Liu Z, Zheng Y, et al
    Head-to-Head Comparison of [(68)Ga]Ga-NOTA-RM26 and [(18)F]FDG PET/CT in Patients with Gastrointestinal Stromal Tumors: A Prospective Study.
    J Nucl Med. 2024 Oct 24:jnumed.124.267810. doi: 10.2967/jnumed.124.267810.
    >> Share

  241. MORRIS ED, Emvalomenos GM, Hoye J, Meikle SR, et al
    Modeling PET Data Acquired During Nonsteady Conditions: What If Brain Conditions Change During the Scan?
    J Nucl Med. 2024 Oct 24:jnumed.124.267494. doi: 10.2967/jnumed.124.267494.
    >> Share

  242. KATUGAMPOLA S, Wang J, Howell RW
    MIRD Pamphlet No. 31: MIRDcell V4-Artificial Intelligence Tools to Formulate Optimized Radiopharmaceutical Cocktails for Therapy.
    J Nucl Med. 2024 Oct 24:jnumed.123.267238. doi: 10.2967/jnumed.123.267238.
    >> Share

  243. LEVI J, Das M, Vasanawala MS, Behl D, et al
    [(18)F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy.
    J Nucl Med. 2024 Oct 24:jnumed.124.268253. doi: 10.2967/jnumed.124.268253.
    >> Share

  244. AMEREIN A, Maurer C, Kircher M, Gable A, et al
    Intraarterial Administration of Peptide Receptor Radionuclide Therapy in Patients with Advanced Meningioma: Initial Safety and Efficacy.
    J Nucl Med. 2024 Oct 24:jnumed.124.268217. doi: 10.2967/jnumed.124.268217.
    >> Share

  245. BOSS M, Eriksson O, Mikkola K, Eek A, et al
    Improved Localization of Insulinomas Using (68)Ga-NODAGA-Exendin-4 PET/CT.
    J Nucl Med. 2024 Oct 17:jnumed.124.268158. doi: 10.2967/jnumed.124.268158.
    >> Share

  246. ARBIZU J, Morbelli S, Minoshima S, Barthel H, et al
    SNMMI Procedure Standard/EANM Practice Guideline for Brain [(18)F]FDG PET Imaging, Version 2.0.
    J Nucl Med. 2024 Oct 17:jnumed.124.268754. doi: 10.2967/jnumed.124.268754.
    >> Share

  247. JANNUSCH K, Umutlu L, Kirchner J, Bruckmann NM, et al
    Impact of (18)F-FDG PET/MRI on Therapeutic Management of Women with Newly Diagnosed Breast Cancer: Results from a Prospective Double-Center Trial.
    J Nucl Med. 2024 Oct 10:jnumed.124.268065. doi: 10.2967/jnumed.124.268065.
    >> Share

  248. LIU Q, Xu X, Yang Z, Zhang J, et al
    Granzyme B PET/CT Imaging Evaluates Early Response to Immunotherapy in Gastric Cancer.
    J Nucl Med. 2024 Oct 10:jnumed.124.267529. doi: 10.2967/jnumed.124.267529.
    >> Share

  249. GAFITA A, Menard AR, Solnes LB
    Diagnostic Radiopharmaceuticals: A Sustainable Path to the Improvement of Patient Care.
    J Nucl Med. 2024 Oct 10:jnumed.124.268608. doi: 10.2967/jnumed.124.268608.
    >> Share

  250. HOTTA M, Kim GHJ, Rerkpichaisuth V, Teng PY, et al
    Correlation of FAPI PET Uptake with Immunohistochemistry in Explanted Lungs from Patients with Advanced Interstitial Lung Disease.
    J Nucl Med. 2024 Oct 3:jnumed.124.268351. doi: 10.2967/jnumed.124.268351.
    >> Share

  251. PELLETIER-GALARNEAU M, Simard F, Tadros R, Tremblay-Gravel M, et al
    Arrhythmias in Nongranulomatous Myocarditis: Is There a Role for PET?
    J Nucl Med. 2024 Oct 3:jnumed.124.268033. doi: 10.2967/jnumed.124.268033.
    >> Share

  252. PRATT EC, Mezzadra R, Kulick A, Kaminsky S, et al
    uPAR Immuno-PET in Pancreatic Cancer, Aging, and Chemotherapy-Induced Senescence.
    J Nucl Med. 2024 Oct 3:jnumed.124.268278. doi: 10.2967/jnumed.124.268278.
    >> Share

  253. FERRANDEZ MC, Golla SSV, Eertink JJ, Wiegers SE, et al
    Validation of an Artificial Intelligence-Based Prediction Model Using 5 External PET/CT Datasets of Diffuse Large B-Cell Lymphoma.
    J Nucl Med. 2024 Oct 3:jnumed.124.268191. doi: 10.2967/jnumed.124.268191.
    >> Share

  254. CARLSEN EA, Loft M, Johnbeck CB, Knigge U, et al
    Routine Use of [(64)Cu]Cu-DOTATATE PET/CT in a Neuroendocrine Tumor Center: Referral Patterns and Image Results of 2,249 Consecutive Scans.
    J Nucl Med. 2024 Oct 3:jnumed.124.267939. doi: 10.2967/jnumed.124.267939.
    >> Share

  255. CALAIS J, Morris MJ, Kendi AT, Kalebasty AR, et al
    Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy.
    J Nucl Med. 2024 Oct 3:jnumed.124.268363. doi: 10.2967/jnumed.124.268363.
    >> Share

  256. LEE H, Alhamshari AS, Patel V, Bhattaru A, et al
    Cardiac Neuroendocrine Tumor Metastases on (68)Ga-DOTATATE PET/CT: Identification and Prognostic Significance.
    J Nucl Med. 2024 Oct 3:jnumed.124.267948. doi: 10.2967/jnumed.124.267948.
    >> Share

  257. MILLER RJH, Lemley M, Shanbhag A, Ramirez G, et al
    The Updated Registry of Fast Myocardial Perfusion Imaging with Next-Generation SPECT (REFINE SPECT 2.0).
    J Nucl Med. 2024 Oct 3:jnumed.124.268292. doi: 10.2967/jnumed.124.268292.
    >> Share

  258. PISANO G, van Oosterom MN, Berrens AC, Slof LJ, et al
    Freehand SPECT Combined with 3-Dimensional Light Detection and Ranging as Alternative Means of Specimen Scanning During Prostate Cancer Surgery.
    J Nucl Med. 2024 Oct 3:jnumed.124.268256. doi: 10.2967/jnumed.124.268256.
    >> Share

  259. RYU J, Hyung J, Han S, Jeong JH, et al
    Impact of (18)F-FES PET/CT on Clinical Decisions in the Management of Recurrent or Metastatic Breast Cancer.
    J Nucl Med. 2024 Oct 3:jnumed.124.267913. doi: 10.2967/jnumed.124.267913.
    >> Share

  260. ZHANG X, Lin Z, Feng Y, Lin Z, et al
    Predicting Pathologic Complete Response in Locally Advanced Rectal Cancer with [(68)Ga]Ga-FAPI-04 PET, [(18)F]FDG PET, and Contrast-Enhanced MRI: Lesion-to-Lesion Comparison with Pathology.
    J Nucl Med. 2024;65:1548-1556.
    >> Share

  261. VAN SLUIS J, van Snick JH, Glaudemans AWJM, Slart RHJA, et al
    Ultrashort Oncologic Whole-Body [(18)F]FDG Patlak Imaging Using LAFOV PET.
    J Nucl Med. 2024;65:1652-1657.
    >> Share

  262. ENKE JS, Ritzel K, Asbach E, Reitsam NG, et al
    C-X-C Motif Chemokine Receptor 4-Directed Scintigraphy Using [(99m)Tc]Tc-Pentixatec in Primary Aldosteronism: A Proof-of-Concept Study.
    J Nucl Med. 2024;65:1640-1644.
    >> Share

  263. ROOHANI B, Mendez AS, Dangarwala M, Katz S, et al
    Nuclear Imaging of Bispecific Antibodies on the Rise.
    J Nucl Med. 2024;65:1512-1517.
    >> Share

    September 2024
  264. DONG Y, Wang Z, Hu X, Sun Y, et al
    [(18)F]AlF-NOTA-FAPI-04 PET/CT for Predicting Pathologic Response of Resectable Esophageal Squamous Cell Carcinoma to Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial.
    J Nucl Med. 2024 Sep 26:jnumed.124.268557. doi: 10.2967/jnumed.124.268557.
    >> Share

  265. BERNARDINO RM, Lajkosz K, Yin LB, Sayyid RK, et al
    Association of Free-to-Total PSA Ratio and (18)F-DCFPyL Prostate-Specific Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After Radical Prostatectomy: A Prospective Single-Center Study.
    J Nucl Med. 2024 Sep 26:jnumed.124.267877. doi: 10.2967/jnumed.124.267877.
    >> Share

  266. POULIOT F, Saad F, Rousseau E, Richard PO, et al
    Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.
    J Nucl Med. 2024 Sep 26:jnumed.124.268020. doi: 10.2967/jnumed.124.268020.
    >> Share

  267. PALESTRO CJ, Abikhzer G, Bar-Sever Z, Bartel T, et al
    Summary: Appropriate Use Criteria for the Use of Nuclear Medicine in Fever of Unknown Origin.
    J Nucl Med. 2024 Sep 26:jnumed.124.268797. doi: 10.2967/jnumed.124.268797.
    >> Share

  268. BYUN JW, Paeng JC, Kim YJ, Lee SP, et al
    Evaluation of Fibroblast Activation Protein Expression Using (68)Ga-FAPI46 PET in Hypertension-Induced Tissue Changes.
    J Nucl Med. 2024 Sep 26:jnumed.124.267489. doi: 10.2967/jnumed.124.267489.
    >> Share

  269. JADVAR H, Iravani A, Bodei L, Calais J, et al
    Challenges with (177)Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice.
    J Nucl Med. 2024 Sep 19:jnumed.124.268023. doi: 10.2967/jnumed.124.268023.
    >> Share

  270. YOUNG JJ, O'Dell RS, Naganawa M, Toyonaga T, et al
    Validation of a Simplified Tissue-to-Reference Ratio Measurement Using SUVR to Assess Synaptic Density Alterations in Alzheimer Disease with [(11)C]UCB-J PET.
    J Nucl Med. 2024 Sep 19:jnumed.124.267419. doi: 10.2967/jnumed.124.267419.
    >> Share

  271. TUNCER O, Steinberger D, Steiner J, Hinojos M, et al
    Quantitative SPECT/CT Metrics in Early Prediction of [(177)Lu]Lu-DOTATATE Treatment Response in Gastroenteropancreatic Neuroendocrine Tumor Patients.
    J Nucl Med. 2024 Sep 12:jnumed.124.267964. doi: 10.2967/jnumed.124.267964.
    >> Share

  272. POOT AJ, Lapa C, Weber WA, Lam MGEH, et al
    [(68)Ga]Ga-RAYZ-8009: A Glypican-3-Targeted Diagnostic Radiopharmaceutical for Hepatocellular Carcinoma Molecular Imaging-A First-in-Human Case Series.
    J Nucl Med. 2024 Sep 12:jnumed.124.268147. doi: 10.2967/jnumed.124.268147.
    >> Share

  273. METSER U, Nunez JE, Chan D, Kulanthaivelu R, et al
    Dual Somatostatin Receptor/(18)F-FDG PET/CT Imaging in Patients with Well-Differentiated, Grade 2 and 3 Gastroenteropancreatic Neuroendocrine Tumors.
    J Nucl Med. 2024 Sep 12:jnumed.124.267982. doi: 10.2967/jnumed.124.267982.
    >> Share

  274. AL-IBRAHEEM A, Abdlkadir A, Herrmann K, Bomanji J, et al
    Diagnostic Accuracy of [(18)F]FDG PET/MRI in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Metaanalysis.
    J Nucl Med. 2024 Sep 12:jnumed.124.268049. doi: 10.2967/jnumed.124.268049.
    >> Share

  275. ALAKONYA H, Koustoulidou S, Hopkins SL, Veal M, et al
    Molecular Imaging of p53 in Mouse Models of Cancer Using a Radiolabeled Antibody TAT Conjugate with SPECT.
    J Nucl Med. 2024 Sep 12:jnumed.124.267736. doi: 10.2967/jnumed.124.267736.
    >> Share

  276. GALBIATI A, Bocci M, Ravazza D, Mock J, et al
    Preclinical Evaluation of (177)Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors.
    J Nucl Med. 2024 Sep 12:jnumed.124.268200. doi: 10.2967/jnumed.124.268200.
    >> Share

  277. POTY S, Ordas L, Dekempeneer Y, Parach AA, et al
    Optimizing the Therapeutic Index of sdAb-Based Radiopharmaceuticals Using Pretargeting.
    J Nucl Med. 2024 Sep 12:jnumed.124.267624. doi: 10.2967/jnumed.124.267624.
    >> Share

  278. WRAY R, Mauguen A, Michaud L, Leithner D, et al
    Development of (18)F-Fluoromisonidazole Hypoxia PET/CT Diagnostic Interpretation Criteria and Validation of Interreader Reliability, Reproducibility, and Performance.
    J Nucl Med. 2024 Sep 12:jnumed.124.267775. doi: 10.2967/jnumed.124.267775.
    >> Share

  279. SULLIVAN R, Hou J, Yu L, Wilk B, et al
    Design, Synthesis, and Preclinical Evaluation of a High-Affinity (18)F-Labeled Radioligand for Myocardial Growth Hormone Secretagogue Receptor Before and After Myocardial Infarction.
    J Nucl Med. 2024 Sep 12:jnumed.124.267578. doi: 10.2967/jnumed.124.267578.
    >> Share

  280. SIVAKUMARAN T, Cardin A, Callahan J, Wong HL, et al
    Evaluating the Utility of (18)F-FDG PET/CT in Cancer of Unknown Primary.
    J Nucl Med. 2024 Sep 5:jnumed.123.267274. doi: 10.2967/jnumed.123.267274.
    >> Share

  281. EISSES B, van Geel JJL, Brouwers AH, Bensch F, et al
    Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer.
    J Nucl Med. 2024 Sep 5:jnumed.124.267636. doi: 10.2967/jnumed.124.267636.
    >> Share

  282. BAUCKNEHT M, D'Amico F, Albano D, Balma M, et al
    Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [(18)F]PSMA-1007 PET/CT.
    J Nucl Med. 2024 Sep 5:jnumed.124.267751. doi: 10.2967/jnumed.124.267751.
    >> Share

  283. KULKARNI HR, Maupin KA, Brennan T, Forsberg J, et al
    First-in-Human Total-Body PET/CT Imaging Using (89)Zr-Labeled MUC5AC Antibody in a Patient with Pancreatic Adenocarcinoma.
    J Nucl Med. 2024 Sep 5:jnumed.124.268074. doi: 10.2967/jnumed.124.268074.
    >> Share


  284. Robert Carretta, MD, 1941-2023.
    J Nucl Med. 2024;65:1498.
    >> Share

  285. BEHRENBRUCH C
    FINDing the Future of Radiopharma.
    J Nucl Med. 2024;65:1333-1335.
    >> Share

    August 2024
  286. KIM D, Kang SK, Shin SA, Choi H, et al
    Improving (18)F-FDG PET Quantification Through a Spatial Normalization Method.
    J Nucl Med. 2024 Aug 29:jnumed.123.267360. doi: 10.2967/jnumed.123.267360.
    >> Share

  287. MWANIA MM, Gitau SN, Shah J, Makhdomi K, et al
    Association Between CA 15-3 and (18)F-FDG PET/CT Findings in Recurrent Breast Cancer Patients at a Tertiary Referral Hospital in Kenya.
    J Nucl Med. 2024 Aug 29:jnumed.124.267851. doi: 10.2967/jnumed.124.267851.
    >> Share

  288. THIN P, Hotta M, Gafita A, Grogan T, et al
    Clinical Factors That Influence Repeat (68)Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative (68)Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study.
    J Nucl Med. 2024 Aug 21:jnumed.124.267591. doi: 10.2967/jnumed.124.267591.
    >> Share

  289. HO KV, Tatum DS, Watkinson L, Carmack T, et al
    Single Chelator-Minibody Theranostic Agents for (89)Zr PET Imaging and (177)Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer.
    J Nucl Med. 2024 Aug 14:jnumed.124.267667. doi: 10.2967/jnumed.124.267667.
    >> Share

  290. INCE S, Laforest R, Itani M, Prasad V, et al
    Quantitative Assessments of Tumor Activity in a General Oncologic PET/CT Population: Which Metric Minimizes Tracer Uptake Time Dependence?
    J Nucl Med. 2024 Aug 14:jnumed.123.266469. doi: 10.2967/jnumed.123.266469.
    >> Share

  291. PANDIT-TASKAR N, Zanzonico PB, Grkovski M, Donzelli M, et al
    Theranostic Intratumoral Convection-Enhanced Delivery of (124)I-Omburtamab in Patients with Diffuse Intrinsic Pontine Glioma: Pharmacokinetics and Lesion Dosimetry.
    J Nucl Med. 2024 Aug 14:jnumed.123.266365. doi: 10.2967/jnumed.123.266365.
    >> Share

  292. MAINTA IC, Neroladaki A, Wolf NB, Benamran D, et al
    [(68)Ga]Ga-PSMA-11 PET and Prostate Cancer Bone Metastases: Diagnostic Performance of Available Standardized Criteria.
    J Nucl Med. 2024 Aug 8:jnumed.124.267899. doi: 10.2967/jnumed.124.267899.
    >> Share

  293. YADAV S, Lowery B, Tuchayi AM, Jiang F, et al
    Impact of Posttreatment SPECT/CT on Patient Management During (177)Lu-PSMA-617 Radiopharmaceutical Therapy.
    J Nucl Med. 2024 Aug 8:jnumed.124.267955. doi: 10.2967/jnumed.124.267955.
    >> Share

  294. OSMAN MM, Iravani A, Mitchell C, Hicks RJ, et al
    (18)F-DCFPyL PSMA PET/CT Tracheobronchial Uptake in Patients with Prostate Cancer: Incidence and Etiology.
    J Nucl Med. 2024 Aug 1:jnumed.124.267772. doi: 10.2967/jnumed.124.267772.
    >> Share

  295. LI S, Nguyen A, Counter W, John NC, et al
    Utility of (64)Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on (68)Ga-PSMA-11 PET/CT.
    J Nucl Med. 2024 Aug 1:jnumed.124.267881. doi: 10.2967/jnumed.124.267881.
    >> Share

  296. BOELLAARD R, Buvat I, Nioche C, Ceriani L, et al
    International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline (18)F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation.
    J Nucl Med. 2024 Aug 1:jnumed.124.267789. doi: 10.2967/jnumed.124.267789.
    >> Share

  297. NIKITAS J, Castellanos Rieger A, Farolfi A, Seyedroudbari A, et al
    Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Aug 1:jnumed.124.267922. doi: 10.2967/jnumed.124.267922.
    >> Share

  298. RIETBERGEN DDD, Buckle T, Slof LJ, van Meerbeek MP, et al
    hHEPATO-Cy5, a Bimodal Tracer for Image-Guided Hepatobiliary Surgery.
    J Nucl Med. 2024;65:1301-1306.
    >> Share

  299. SCHELBERT H, Schoder H, Czernin J
    Illuminating Cardiac Function: Heinz Schelbert Talks with Heiko Schoder and Johannes Czernin About a Pioneering Career in Nuclear Cardiology.
    J Nucl Med. 2024;65:1163-1165.
    >> Share

  300. RESCH S, Ziegler SI, Sheikh G, Unterrainer LM, et al
    Impact of the Reference Multiple-Time-Point Dosimetry Protocol on the Validity of Single-Time-Point Dosimetry for [(177)Lu]Lu-PSMA-I&T Therapy.
    J Nucl Med. 2024;65:1272-1278.
    >> Share

  301. ANGAPPULIGE DH, Barashi NS, Pickersgill N, Weimholt C, et al
    Prostate-Specific Membrane Antigen-Targeted Imaging and Its Correlation with HOXB13 Expression.
    J Nucl Med. 2024;65:1210-1216.
    >> Share

  302. CAPTIER N, Orlhac F, Hovhannisyan-Baghdasarian N, Luporsi M, et al
    RadShap: An Explanation Tool for Highlighting the Contributions of Multiple Regions of Interest to the Prediction of Radiomic Models.
    J Nucl Med. 2024;65:1307-1312.
    >> Share

  303. LUDWIG V, Maliha PG, Shen J, Tonnelet D, et al
    [(68)Ga]Ga-FAPI-46 False-Positive Uptake After Chemotherapy in Nonseminomatous Germ Cell Tumor Metastatic Lesions.
    J Nucl Med. 2024;65:1328-1329.
    >> Share

    July 2024
  304. BUDDENKOTTE T, Buchert R
    Unrealistic Data Augmentation Improves the Robustness of Deep Learning-Based Classification of Dopamine Transporter SPECT Against Variability Between Sites and Between Cameras.
    J Nucl Med. 2024 Jul 25:jnumed.124.267570. doi: 10.2967/jnumed.124.267570.
    >> Share

  305. PICCARDO A, Bottoni G, Puppo C, Massollo M, et al
    Role of (64)CuCl(2) PET/CT in Detecting and Staging Muscle-Invasive Bladder Cancer: Comparison with Contrast-Enhanced CT and (18)F-FDG PET/CT.
    J Nucl Med. 2024 Jul 25:jnumed.124.267474. doi: 10.2967/jnumed.124.267474.
    >> Share

  306. GEBRE RK, Rial AM, Raghavan S, Wiste HJ, et al
    Advancing Tau PET Quantification in Alzheimer Disease with Machine Learning: Introducing THETA, a Novel Tau Summary Measure.
    J Nucl Med. 2024 Jul 25:jnumed.123.267273. doi: 10.2967/jnumed.123.267273.
    >> Share

  307. PIROZZI MA, Gaudieri V, Prinster A, Magliulo M, et al
    StepBrain: A 3-Dimensionally Printed Multicompartmental Anthropomorphic Brain Phantom to Simulate PET Activity Distributions.
    J Nucl Med. 2024 Jul 18:jnumed.123.267277. doi: 10.2967/jnumed.123.267277.
    >> Share

  308. BASACO BERNABEU T, Mansi R, Del Pozzo L, Zanger S, et al
    (61)Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging.
    J Nucl Med. 2024 Jul 18:jnumed.123.267126. doi: 10.2967/jnumed.123.267126.
    >> Share

  309. KANG F, Xie Z, Ma W, Quan Z, et al
    Validation and Evaluation of a Vendor-Provided Head Motion Correction Algorithm on the uMI Panorama PET/CT System.
    J Nucl Med. 2024 Jul 11:jnumed.124.267446. doi: 10.2967/jnumed.124.267446.
    >> Share

  310. LARIVE T, Boursier C, Claudin M, Varlot J, et al
    Factors Associated with Myocardial Uptake on Oncologic Somatostatin PET Investigations and Differentiation from Myocardial Uptake of Acute Myocarditis.
    J Nucl Med. 2024 Jul 11:jnumed.123.267219. doi: 10.2967/jnumed.123.267219.
    >> Share

  311. CLEMENT C, Leclere JC, Maheo C, Le Pennec R, et al
    Diagnostic Performance of (18)F-FDG PET/CT According to Delay After Treatment to Detect Subclinical Recurrence of Head and Neck Squamous Cell Carcinoma.
    J Nucl Med. 2024 Jul 11:jnumed.124.267391. doi: 10.2967/jnumed.124.267391.
    >> Share

  312. KESSLER L, Schwaning F, Metzenmacher M, Pabst K, et al
    Fibroblast Activation Protein-Directed Imaging Outperforms (18)F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial.
    J Nucl Med. 2024 Jul 3:jnumed.124.267473. doi: 10.2967/jnumed.124.267473.
    >> Share

  313. OSTER C, Kessler L, Blau T, Keyvani K, et al
    The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma: A Comparison of Tissue, (68)Ga-FAPI-46 PET Data, and Survival Data.
    J Nucl Med. 2024 Jul 3:jnumed.123.267151. doi: 10.2967/jnumed.123.267151.
    >> Share

  314. BORGWARDT L, Brok J, Andersen KF, Madsen J, et al
    Performing [(18)F]MFBG Long-Axial-Field-of-View PET/CT Without Sedation or General Anesthesia for Imaging of Children with Neuroblastoma.
    J Nucl Med. 2024 Jul 3:jnumed.123.267256. doi: 10.2967/jnumed.123.267256.
    >> Share

  315. ELLS Z, Grogan TR, Czernin J, Dahlbom M, et al
    Dosimetry of [(177)Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis.
    J Nucl Med. 2024 Jul 3:jnumed.124.267452. doi: 10.2967/jnumed.124.267452.
    >> Share

  316. LU Z, Polan DF, Wei L, Aryal MP, et al
    PET/CT-Based Absorbed Dose Maps in (90)Y Selective Internal Radiation Therapy Correlate with Spatial Changes in Liver Function Derived from Dynamic MRI.
    J Nucl Med. 2024 Jul 3:jnumed.124.267421. doi: 10.2967/jnumed.124.267421.
    >> Share

  317. WARFVINGE CF, Gustafsson J, Roth D, Tennvall J, et al
    Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [(177)Lu]Lu-DOTATATE.
    J Nucl Med. 2024;65:1070-1075.
    >> Share

    June 2024
  318. COMBET-CURT V, Buchalet C, Malicot KL, Lemanski C, et al
    Prognostic Value of (18)F-FDG PET/CT Assessment After Radiotherapy of Squamous Cell Carcinoma of the Anus in Patients from the National Multicentric Cohort FFCD-ANABASE.
    J Nucl Med. 2024 Jun 27:jnumed.124.267626. doi: 10.2967/jnumed.124.267626.
    >> Share

  319. BAUCKNEHT M, Lanfranchi F, Albano D, Triggiani L, et al
    Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study).
    J Nucl Med. 2024 Jun 27:jnumed.124.267586. doi: 10.2967/jnumed.124.267586.
    >> Share

  320. LAVERDIERE I, Matte G, Darveau M, Beauregard JM, et al
    Nuclear Pharmacy Training in the Era of Theranostics: Toward Meeting the Needs of Nuclear Medicine Patients for Comprehensive Pharmaceutical Care.
    J Nucl Med. 2024 Jun 21:jnumed.124.267603. doi: 10.2967/jnumed.124.267603.
    >> Share

  321. LI H, Badawi RD, Cherry SR, Fontaine K, et al
    Performance Characteristics of the NeuroEXPLORER, a Next-Generation Human Brain PET/CT Imager.
    J Nucl Med. 2024 Jun 13:jnumed.124.267767. doi: 10.2967/jnumed.124.267767.
    >> Share

  322. MONASTERO F, Vetrone L, Cardisciani L, Renzulli M, et al
    [(68)Ga]Ga-PSMA-11 PET/CT-Positive Hepatic Inflammatory Pseudotumor: Possible PSMA-Avid Pitfall in Nuclear Imaging.
    J Nucl Med. 2024 Jun 13:jnumed.124.267518. doi: 10.2967/jnumed.124.267518.
    >> Share

  323. FONSECA CABRERA GO, Ma X, Lin W, Zhang T, et al
    Synthesis of (64)Cu-, (55)Co-, and (68)Ga-Labeled Radiopharmaceuticals Targeting Neurotensin Receptor-1 for Theranostics: Adjusting In Vivo Distribution Using Multiamine Macrocycles.
    J Nucl Med. 2024 Jun 13:jnumed.124.267469. doi: 10.2967/jnumed.124.267469.
    >> Share

  324. MUKKAMALA R, Carlson DJ, Miller NK, Lindeman SD, et al
    Design of a Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy with High Tumor-to-Healthy-Tissue Ratios.
    J Nucl Med. 2024 Jun 13:jnumed.124.267756. doi: 10.2967/jnumed.124.267756.
    >> Share

  325. KUO PH, Esposito G, Ulaner GA, Yoo D, et al
    Interreader and Intrareader Reproducibility of (18)F-Flotufolastat Image Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer: Data from Two Phase 3 Prospective Multicenter Studies.
    J Nucl Med. 2024 Jun 13:jnumed.123.267306. doi: 10.2967/jnumed.123.267306.
    >> Share

  326. PHAM TT, Chenoweth A, Patel N, Banu A, et al
    In Vivo PET Imaging of (89)Zr-Labeled Natural Killer Cells and the Modulating Effects of a Therapeutic Antibody.
    J Nucl Med. 2024 Jun 6:jnumed.124.267876. doi: 10.2967/jnumed.124.267876.
    >> Share

  327. EVANGELISTA L, Zattoni F, Burei M, Bertin D, et al
    A Prospective Randomized Multicenter Study on the Impact of [(18)F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer.
    J Nucl Med. 2024 Jun 6:jnumed.123.267355. doi: 10.2967/jnumed.123.267355.
    >> Share

  328. SHIYAM SUNDAR LK, Beyer T
    Is Automatic Tumor Segmentation on Whole-Body (18)F-FDG PET Images a Clinical Reality?
    J Nucl Med. 2024 Jun 6:jnumed.123.267183. doi: 10.2967/jnumed.123.267183.
    >> Share

  329. NADEL HR
    Innovation and Dedication Spur Excellence in Nuclear Medicine and Molecular Imaging.
    J Nucl Med. 2024;65:11A-12A.
    >> Share

  330. CZERNIN J
    JNM Editors' Choice Awards for 2023.
    J Nucl Med. 2024;65:825.
    >> Share

  331. BEEKMAN F, Czernin J, Mona C
    Inventing His Own Career Path: Freek Beekman Talks with Johannes Czernin and Christine Mona About Success in Academia and Industry.
    J Nucl Med. 2024;65:826-828.
    >> Share

  332. RICH AA, Taunk NK, Mankoff DA, Pantel AR, et al
    [(18)F]Fluoroestradiol Uptake in Irradiated Lung Parenchyma and Draining Nodes.
    J Nucl Med. 2024;65:990-991.
    >> Share

    May 2024
  333. LECY EE, Min HK, Apgar CJ, Maltais DD, et al
    Patterns of Early Neocortical Amyloid-beta Accumulation: A PET Population-Based Study.
    J Nucl Med. 2024 May 23:jnumed.123.267150. doi: 10.2967/jnumed.123.267150.
    >> Share

  334. IMBERTI C, De Gregorio R, Korsen JA, Hoang TT, et al
    CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer.
    J Nucl Med. 2024 May 23:jnumed.123.267107. doi: 10.2967/jnumed.123.267107.
    >> Share

  335. SMEETS EMM, Trajkovic-Arsic M, Geijs D, Karakaya S, et al
    Histology-Based Radiomics for [(18)F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer.
    J Nucl Med. 2024 May 23:jnumed.123.266262. doi: 10.2967/jnumed.123.266262.
    >> Share

  336. WATANABE M, Fendler WP, Grafe H, Hirmas N, et al
    Prognostic Implications of (68)Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid Tumors.
    J Nucl Med. 2024 May 23:jnumed.123.266981. doi: 10.2967/jnumed.123.266981.
    >> Share

  337. SADAGHIANI MS, Baskaran S, Gorin MA, Rowe SP, et al
    Utility of PSMA PET/CT in Staging and Restaging of Renal Cell Carcinoma: A Systematic Review and Metaanalysis.
    J Nucl Med. 2024 May 23:jnumed.124.267417. doi: 10.2967/jnumed.124.267417.
    >> Share

  338. FLEMING MT, Hermsen R, Purysko AS, Chau A, et al
    True-Positive (18)F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study.
    J Nucl Med. 2024 May 23:jnumed.123.267271. doi: 10.2967/jnumed.123.267271.
    >> Share

  339. HEIDARI P, Haj-Mirzaian A, Prabhu S, Ataeinia B, et al
    Granzyme B PET Imaging for Assessment of Disease Activity in Inflammatory Bowel Disease.
    J Nucl Med. 2024 May 16:jnumed.123.267344. doi: 10.2967/jnumed.123.267344.
    >> Share

  340. YADAV S, Jiang F, Kurkowska S, Saelee R, et al
    Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection.
    J Nucl Med. 2024 May 9:jnumed.123.267208. doi: 10.2967/jnumed.123.267208.
    >> Share

  341. CAOBELLI F, Gozlugol N, Bakula A, Rominger A, et al
    Prognostic Value of [(99m)Tc]Tc-DPD Quantitative SPECT/CT in Patients with Suspected and Confirmed Amyloid Transthyretin-Related Cardiomyopathy and Preserved Left Ventricular Function.
    J Nucl Med. 2024 May 9:jnumed.123.266926. doi: 10.2967/jnumed.123.266926.
    >> Share

  342. LANZAFAME H, Mavroeidi IA, Pabst KM, Desaulniers M, et al
    (68)Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy.
    J Nucl Med. 2024 May 9:jnumed.123.267248. doi: 10.2967/jnumed.123.267248.
    >> Share

  343. MILLER RJH, Shanbhag A, Michalowska AM, Kavanagh P, et al
    Deep Learning-Enabled Quantification of (99m)Tc-Pyrophosphate SPECT/CT for Cardiac Amyloidosis.
    J Nucl Med. 2024 May 9:jnumed.124.267542. doi: 10.2967/jnumed.124.267542.
    >> Share

  344. ZANG J, Yang Y, Chen S, Wang C, et al
    Diagnostic Performance of [(18)F]AlF-Thretide PET/CT in Patients with Newly Diagnosed Prostate Cancer Using Histopathology as Reference Standard.
    J Nucl Med. 2024 May 9:jnumed.123.266940. doi: 10.2967/jnumed.123.266940.
    >> Share

  345. HOEK R, van Diemen PA, Raijmakers PG, Driessen RS, et al
    Determining Hemodynamically Significant Coronary Artery Disease: Patient-Specific Cutoffs in Quantitative Myocardial Blood Flow Using [(15)O]H(2)O PET Imaging.
    J Nucl Med. 2024 May 9:jnumed.123.267195. doi: 10.2967/jnumed.123.267195.
    >> Share

  346. DIETZ M, Kamani CH, Bousige C, Dunet V, et al
    Natural History of Myocardial alpha(v)beta(3) Integrin Expression After Acute Myocardial Infarction: Correlation with Changes in Myocardial Blood Flow.
    J Nucl Med. 2024 May 9:jnumed.124.267514. doi: 10.2967/jnumed.124.267514.
    >> Share

  347. WU Y, Sun T, Ng YL, Liu J, et al
    Clinical Implementation of Total-Body PET in China.
    J Nucl Med. 2024;65.
    >> Share

  348. ZHANG J, Duan X, Chen X, Zhang Z, et al
    Translational PET Imaging of Nectin-4 Expression in Multiple Different Cancers with (68)Ga-N188.
    J Nucl Med. 2024;65.
    >> Share

  349. MENG X, Kong X, Xia L, Wu R, et al
    The Role of Total-Body PET in Drug Development and Evaluation: Status and Outlook.
    J Nucl Med. 2024;65.
    >> Share

  350. YANG W, Kang F, Chen Y, Zhu Z, et al
    Landscape of Nuclear Medicine in China and Its Progress on Theranostics.
    J Nucl Med. 2024;65.
    >> Share

  351. AN S, Wang L, Xie F, Jiang D, et al
    Pathway to Approval of Innovative Radiopharmaceuticals in China.
    J Nucl Med. 2024;65.
    >> Share

  352. CHEN H, Shi K, Cai W, Li S, et al
    Advancing Global Nuclear Medicine: The Role and Future Contributions of China.
    J Nucl Med. 2024;65.
    >> Share

  353. ZHAO L, Kang F, Pang Y, Fang J, et al
    Fibroblast Activation Protein Inhibitor Tracers and Their Preclinical, Translational, and Clinical Status in China.
    J Nucl Med. 2024;65.
    >> Share

  354. CHEN W, Li Y, Li Z, Jiang Y, et al
    Advantages and Challenges of Total-Body PET/CT at a Tertiary Cancer Center: Insights from Sun Yat-sen University Cancer Center.
    J Nucl Med. 2024;65.
    >> Share

  355. KLINE B, Yadav S, Seo Y, Ippisch RC, et al
    (68)Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with (18)F-FDG.
    J Nucl Med. 2024 May 2:jnumed.123.267281. doi: 10.2967/jnumed.123.267281.
    >> Share

  356. MA Y, Zeng J, Ding F, Xu Y, et al
    Cerebral (18)F-FDG PET/CT Metabolism as Diagnostic Signature for Central Nervous System Toxicity After Immune Checkpoint Blockade Cancer Treatment.
    J Nucl Med. 2024 May 2:jnumed.123.267025. doi: 10.2967/jnumed.123.267025.
    >> Share

  357. FEHER A, Bednarski B, Miller RJ, Shanbhag A, et al
    Artificial Intelligence Predicts Hospitalization for Acute Heart Failure Exacerbation in Patients Undergoing Myocardial Perfusion Imaging.
    J Nucl Med. 2024;65:768-774.
    >> Share


  358. Gerald L. DeNardo, MD, 1932-2024.
    J Nucl Med. 2024;65:823.
    >> Share

    April 2024
  359. ROSEN J, Werner JM, Ceccon GS, Rosen EK, et al
    MRI and (18)F-FET PET for Multimodal Treatment Monitoring in Patients with Brain Metastases: A Cost-Effectiveness Analysis.
    J Nucl Med. 2024 Apr 25:jnumed.123.266687. doi: 10.2967/jnumed.123.266687.
    >> Share

  360. NIKITAS J, Lam E, Booker KA, Fendler WP, et al
    Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial).
    J Nucl Med. 2024 Apr 25:jnumed.123.267004. doi: 10.2967/jnumed.123.267004.
    >> Share

  361. MINGELS C, Spencer BA, Nalbant H, Omidvari N, et al
    Dose Reduction in Pediatric Oncology Patients with Delayed Total-Body [(18)F]FDG PET/CT.
    J Nucl Med. 2024 Apr 25:jnumed.124.267521. doi: 10.2967/jnumed.124.267521.
    >> Share

  362. DUAN H, Song H, Davidzon GA, Moradi F, et al
    Prospective Comparison of (68)Ga-NeoB and (68)Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer.
    J Nucl Med. 2024 Apr 25:jnumed.123.267017. doi: 10.2967/jnumed.123.267017.
    >> Share

  363. BURKETT BJ, Johnson DR, Lowe VJ
    Evaluation of Neurodegenerative Disorders with Amyloid-beta, Tau, and Dopaminergic PET Imaging: Interpretation Pitfalls.
    J Nucl Med. 2024 Apr 25:jnumed.123.266463. doi: 10.2967/jnumed.123.266463.
    >> Share

  364. GAFITA A, Djaileb L, Rauscher I, Fendler WP, et al
    RECIP 1.0 Predicts Progression-Free Survival After [(177)Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Apr 18:jnumed.123.267234. doi: 10.2967/jnumed.123.267234.
    >> Share

  365. LEUBE J, Gustafsson J, Lassmann M, Salas-Ramirez M, et al
    A Deep-Learning-Based Partial-Volume Correction Method for Quantitative (177)Lu SPECT/CT Imaging.
    J Nucl Med. 2024 Apr 18:jnumed.123.266889. doi: 10.2967/jnumed.123.266889.
    >> Share

  366. HAGENS MJ, van Leeuwen PJ, Wondergem M, Boellaard TN, et al
    A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET/CT in Genitourinary Cancers.
    J Nucl Med. 2024 Apr 18:jnumed.123.267260. doi: 10.2967/jnumed.123.267260.
    >> Share

  367. MOSER R, Pfeiffer S, Cala L, Klein E, et al
    Detecting Metastatic Patterns of Oligometastatic Breast Cancer: A Comparative Analysis of (18)F-FDG PET/CT and Conventional CT Imaging.
    J Nucl Med. 2024 Apr 18:jnumed.123.266925. doi: 10.2967/jnumed.123.266925.
    >> Share

  368. SWIHA M, Papa N, Sabahi Z, Ayati N, et al
    Development of a Visually Calculated SUV(mean) (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to (177)Lu-PSMA Therapy: Comparison with Quantitative SUV(mean) and Patient Outcomes.
    J Nucl Med. 2024 Apr 18:jnumed.123.267014. doi: 10.2967/jnumed.123.267014.
    >> Share

  369. QI C, Guo R, Chen Y, Li C, et al
    (68)Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal Cancer Patients.
    J Nucl Med. 2024 Apr 11:jnumed.123.267110. doi: 10.2967/jnumed.123.267110.
    >> Share

  370. ROHRICH M, Daum J, Gutjahr E, Spektor AM, et al
    Diagnostic Potential of Supplemental Static and Dynamic (68)Ga-FAPI-46 PET for Primary (18)F-FDG-Negative Pulmonary Lesions.
    J Nucl Med. 2024 Apr 11:jnumed.123.267103. doi: 10.2967/jnumed.123.267103.
    >> Share

  371. O'DONNELL JL, Soda AK, Jiang H, Norris SA, et al
    PET Quantification of [(18)F]VAT in Human Brain and Its Test-Retest Reproducibility and Age Dependence.
    J Nucl Med. 2024 Apr 11:jnumed.123.266860. doi: 10.2967/jnumed.123.266860.
    >> Share

  372. VISCUSE P, Devitt M, Dreicer R
    Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?
    J Nucl Med. 2024 Apr 11:jnumed.123.267006. doi: 10.2967/jnumed.123.267006.
    >> Share

  373. WU Q, Gu F, O'Suilleabhain LD, Sari H, et al
    Mapping (18)F-FDG Kinetics Together with Patient-Specific Bootstrap Assessment of Uncertainties: An Illustration with Data from a PET/CT Scanner with a Long Axial Field of View.
    J Nucl Med. 2024 Apr 11:jnumed.123.266686. doi: 10.2967/jnumed.123.266686.
    >> Share

  374. BARATTO L, Singh SB, Williams SE, Spunt SL, et al
    Detecting High-Dose Methotrexate-Induced Brain Changes in Pediatric and Young Adult Cancer Survivors Using [(18)F]FDG PET/MRI: A Pilot Study.
    J Nucl Med. 2024 Apr 4:jnumed.123.266760. doi: 10.2967/jnumed.123.266760.
    >> Share

  375. GEBHART G, Keyaerts M, Guiot T, Flamen P, et al
    Optimal [(18)F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.
    J Nucl Med. 2024 Apr 4:jnumed.123.266384. doi: 10.2967/jnumed.123.266384.
    >> Share

  376. BISCHOF GN, Brendel M, Barthel H, Theis H, et al
    Improved Tau PET SUVR Quantification in 4-Repeat Tau Phenotypes with [(18)F]PI-2620.
    J Nucl Med. 2024 Apr 4:jnumed.123.265930. doi: 10.2967/jnumed.123.265930.
    >> Share

  377. RUWANPATHIRANA GP, Williams RC, Masters CL, Rowe CC, et al
    Impact of PET Reconstruction on Amyloid-beta Quantitation in Cross-Sectional and Longitudinal Analyses.
    J Nucl Med. 2024 Apr 4:jnumed.123.266188. doi: 10.2967/jnumed.123.266188.
    >> Share

  378. SCHULER M, Hense J, Darwiche K, Michels S, et al
    Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance.
    J Nucl Med. 2024 Apr 4:jnumed.123.266979. doi: 10.2967/jnumed.123.266979.
    >> Share

  379. LI Z, Benabdallah N, Luo J, Wahl RL, et al
    ISIT-QA: In Silico Imaging Trial to Evaluate a Low-Count Quantitative SPECT Method Across Multiple Scanner-Collimator Configurations for (223)Ra-Based Radiopharmaceutical Therapies.
    J Nucl Med. 2024 Apr 4:jnumed.123.266719. doi: 10.2967/jnumed.123.266719.
    >> Share

    March 2024
  380. ALTENA R, Buren SA, Blomgren A, Karlsson E, et al
    Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [(68)Ga]Ga-ABY-025: Results from a Pilot Study.
    J Nucl Med. 2024 Mar 28:jnumed.123.266847. doi: 10.2967/jnumed.123.266847.
    >> Share

  381. COLLARINO A, Feudo V, Pasciuto T, Florit A, et al
    Is PET Radiomics Useful to Predict Pathologic Tumor Response and Prognosis in Locally Advanced Cervical Cancer?
    J Nucl Med. 2024 Mar 28:jnumed.123.267044. doi: 10.2967/jnumed.123.267044.
    >> Share

  382. BLAKKISRUD J, Peterson AB, Wildermann SJ, Kingkiner G, et al
    SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [(177)Lu]Lu-DOTATATE.
    J Nucl Med. 2024 Mar 28:jnumed.123.266843. doi: 10.2967/jnumed.123.266843.
    >> Share

  383. ZHANG X, Heo GS, Li A, Lahad D, et al
    Development of a CD163-Targeted PET Radiotracer That Images Resident Macrophages in Atherosclerosis.
    J Nucl Med. 2024 Mar 28:jnumed.123.266910. doi: 10.2967/jnumed.123.266910.
    >> Share

  384. WANG Y, Abdelhafez YG, Spencer BA, Verma R, et al
    High-Temporal-Resolution Kinetic Modeling of Lung Tumors with Dual-Blood Input Function Using Total-Body Dynamic PET.
    J Nucl Med. 2024 Mar 28:jnumed.123.267036. doi: 10.2967/jnumed.123.267036.
    >> Share

  385. HAIDER SP, Zeevi T, Sharaf K, Gross M, et al
    Impact of (18)F-FDG PET Intensity Normalization on Radiomic Features of Oropharyngeal Squamous Cell Carcinomas and Machine Learning-Generated Biomarkers.
    J Nucl Med. 2024 Mar 21:jnumed.123.266637. doi: 10.2967/jnumed.123.266637.
    >> Share

  386. PRUIS IJ, Verburg FA, Balvers RK, Harteveld AA, et al
    [(18)F]FET PET/MRI: An Accurate Technique for Detection of Small Functional Pituitary Tumors.
    J Nucl Med. 2024 Mar 21:jnumed.123.266853. doi: 10.2967/jnumed.123.266853.
    >> Share

  387. LIU N, Yang X, Gao C, Wang J, et al
    Noninvasively Deciphering the Immunosuppressive Tumor Microenvironment Using Galectin-1 PET to Inform Immunotherapy Responses.
    J Nucl Med. 2024 Mar 21:jnumed.123.266888. doi: 10.2967/jnumed.123.266888.
    >> Share

  388. JAGUST WJ, Mattay VS, Krainak DM, Wang SJ, et al
    Quantitative Brain Amyloid PET.
    J Nucl Med. 2024 Mar 21:jnumed.123.265766. doi: 10.2967/jnumed.123.265766.
    >> Share

  389. CYTRYN SL, Pandit-Taskar N, Lumish MA, Maron SB, et al
    (18)F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer.
    J Nucl Med. 2024 Mar 21:jnumed.123.267186. doi: 10.2967/jnumed.123.267186.
    >> Share

  390. SHI J, Li D, Chen M, Fu Y, et al
    The Value of (68)Ga-PSMA PET/MRI for Classifying Patients with PI-RADS 3 Lesions on Multiparametric MRI: A Prospective Single-Center Study.
    J Nucl Med. 2024 Mar 14:jnumed.123.266742. doi: 10.2967/jnumed.123.266742.
    >> Share

  391. BERRENS AC, Sorbi MA, Donswijk ML, de Barros HA, et al
    Strong Correlation Between SUV(max) on PSMA PET/CT and Numeric Drop-In gamma-Probe Signal for Intraoperative Identification of Prostate Cancer Lesions.
    J Nucl Med. 2024 Mar 14:jnumed.123.267075. doi: 10.2967/jnumed.123.267075.
    >> Share

  392. SAHIN E, Kus T, Aytekin A, Uzun E, et al
    (68)Ga-FAPI PET/CT as an Alternative to (18)F-FDG PET/CT in the Imaging of Invasive Lobular Breast Carcinoma.
    J Nucl Med. 2024 Mar 14:jnumed.123.266798. doi: 10.2967/jnumed.123.266798.
    >> Share

  393. PORTER JC, Ganeshan B, Win T, Fraioli F, et al
    [(18)F]FDG PET/CT Signal Correlates with Neoangiogenesis Markers in Patients with Fibrotic Interstitial Lung Disease Who Underwent Lung Biopsy: Implication for the Use of PET/CT in Diffuse Lung Diseases.
    J Nucl Med. 2024 Mar 14:jnumed.123.266445. doi: 10.2967/jnumed.123.266445.
    >> Share

  394. PROVIDENCIA L, van der Weijden CWJ, Mohr P, van Sluis J, et al
    Can Internal Carotid Arteries Be Used for Noninvasive Quantification of Brain PET Studies?
    J Nucl Med. 2024 Mar 14:jnumed.123.266675. doi: 10.2967/jnumed.123.266675.
    >> Share

  395. THOR M, Lee C, Sun L, Patel P, et al
    An (18)F-FDG PET/CT and Mean Lung Dose Model to Predict Early Radiation Pneumonitis in Stage III Non-Small Cell Lung Cancer Patients Treated with Chemoradiation and Immunotherapy.
    J Nucl Med. 2024 Mar 14:jnumed.123.266965. doi: 10.2967/jnumed.123.266965.
    >> Share

  396. DRESCHER R, Greiser J, Grober S, Weisheit T, et al
    (64)Cu-DOTA Enables Late PET Imaging and Leak Detection in the Cerebrospinal Fluid Space.
    J Nucl Med. 2024 Mar 14:jnumed.123.267329. doi: 10.2967/jnumed.123.267329.
    >> Share

  397. HARTRAMPF PE, Huttmann T, Seitz AK, Kubler H, et al
    Prognostic Performance of RECIP 1.0 Based on [(18)F]PSMA-1007 PET in Prostate Cancer Patients Treated with [(177)Lu]Lu-PSMA I&T.
    J Nucl Med. 2024 Mar 7:jnumed.123.266702. doi: 10.2967/jnumed.123.266702.
    >> Share

  398. LI C, Chen Q, Tian Y, Chen J, et al
    (68)Ga-FAPI-04 PET/CT in Non-Small Cell Lung Cancer: Accurate Evaluation of Lymph Node Metastasis and Correlation with Fibroblast Activation Protein Expression.
    J Nucl Med. 2024 Mar 7:jnumed.123.266806. doi: 10.2967/jnumed.123.266806.
    >> Share

  399. HOVHANNISYAN-BAGHDASARIAN N, Luporsi M, Captier N, Nioche C, et al
    Promising Candidate Prognostic Biomarkers in [(18)F]FDG PET Images: Evaluation in Independent Cohorts of Non-Small Cell Lung Cancer Patients.
    J Nucl Med. 2024 Mar 7:jnumed.123.266331. doi: 10.2967/jnumed.123.266331.
    >> Share

  400. CUZZANI G, Fortunati E, Zanoni L, Nanni C, et al
    Case Report: Pulmonary Actinomyces Infection Mimics Lung Cancer on [(68)Ga]Ga-FAPI PET/CT.
    J Nucl Med. 2024 Mar 7:jnumed.123.267155. doi: 10.2967/jnumed.123.267155.
    >> Share

  401. FAROLFI A, Armstrong WR, Djaileb L, Gafita A, et al
    Differences and Common Ground in (177)Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers.
    J Nucl Med. 2024;65:438-445.
    >> Share

    February 2024
  402. LEUNG KH, Rowe SP, Sadaghiani MS, Leal JP, et al
    Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT.
    J Nucl Med. 2024 Feb 29:jnumed.123.267048. doi: 10.2967/jnumed.123.267048.
    >> Share

  403. JIANG M, Tang S, Jenkins MD, Lee AC, et al
    Robust Quantification of Phosphodiesterase-4D in Monkey Brain with PET and (11)C-Labeled Radioligands That Avoid Radiometabolite Contamination.
    J Nucl Med. 2024 Feb 29:jnumed.123.266750. doi: 10.2967/jnumed.123.266750.
    >> Share

  404. GRIFFITHS MR, Pattison DA, Latter M, Kuan K, et al
    First-in-Human (212)Pb-PSMA-Targeted alpha-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Feb 29:jnumed.123.267189. doi: 10.2967/jnumed.123.267189.
    >> Share

  405. BOSCH D, van der Velden KJM, Oving IM, Wyndaele DNJ, et al
    The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of (223)Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
    J Nucl Med. 2024 Feb 29:jnumed.123.266654. doi: 10.2967/jnumed.123.266654.
    >> Share

  406. EL FAKIRI M, Ayada N, Muller M, Hvass L, et al
    Development and Preclinical Evaluation of [(211)At]PSAt-3-Ga: An Inhibitor for Targeted alpha-Therapy of Prostate Cancer.
    J Nucl Med. 2024 Feb 29:jnumed.123.267043. doi: 10.2967/jnumed.123.267043.
    >> Share

  407. KOVACS DG, Ladefoged CN, Andersen KF, Brittain JM, et al
    Clinical Evaluation of Deep Learning for Tumor Delineation on (18)F-FDG PET/CT of Head and Neck Cancer.
    J Nucl Med. 2024 Feb 22:jnumed.123.266574. doi: 10.2967/jnumed.123.266574.
    >> Share

  408. LI G, Ma W, Li X, Yang W, et al
    Performance Evaluation of the uMI Panorama PET/CT System in Accordance with the National Electrical Manufacturers Association NU 2-2018 Standard.
    J Nucl Med. 2024 Feb 22:jnumed.123.265929. doi: 10.2967/jnumed.123.265929.
    >> Share

  409. SLART RHJA, Bengel FM, Akincioglu C, Bourque JM, et al
    Total-Body PET/CT Applications in Cardiovascular Diseases: A Perspective Document of the SNMMI Cardiovascular Council.
    J Nucl Med. 2024 Feb 22:jnumed.123.266858. doi: 10.2967/jnumed.123.266858.
    >> Share

  410. BOURBONNE V, Morjani M, Pradier O, Hatt M, et al
    PET/CT-Based Radiogenomics Supports KEAP1/NFE2L2 Pathway Targeting for Non-Small Cell Lung Cancer Treated with Curative Radiotherapy.
    J Nucl Med. 2024 Feb 15:jnumed.123.266749. doi: 10.2967/jnumed.123.266749.
    >> Share

  411. LOHMANN P, Gutsche R, Werner JM, Shah NJ, et al
    Example of Artificial Intelligence-Based Decision Support for Amino Acid PET: Early Prediction of Suspected Brain Tumor Foci for Patient Management.
    J Nucl Med. 2024 Feb 15:jnumed.123.267112. doi: 10.2967/jnumed.123.267112.
    >> Share

  412. DRAKE LR, Wu Y, Naganawa M, Asch R, et al
    First-in-Human Study of (18)F-SynVesT-2: An SV2A PET Imaging Probe with Fast Brain Kinetics and High Specific Binding.
    J Nucl Med. 2024 Feb 15:jnumed.123.266470. doi: 10.2967/jnumed.123.266470.
    >> Share

  413. LIU Z, Mhlanga JC, Xia H, Siegel BA, et al
    Need for Objective Task-Based Evaluation of Image Segmentation Algorithms for Quantitative PET: A Study with ACRIN 6668/RTOG 0235 Multicenter Clinical Trial Data.
    J Nucl Med. 2024 Feb 15:jnumed.123.266018. doi: 10.2967/jnumed.123.266018.
    >> Share

  414. KISHAN AU, Siva S, Hofman MS, Nagarajah J, et al
    The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease.
    J Nucl Med. 2024 Feb 15:jnumed.123.266772. doi: 10.2967/jnumed.123.266772.
    >> Share

  415. DUBASH S, Barwick TD, Kozlowski K, Rockall AG, et al
    Somatostatin Receptor Imaging with [(18)F]FET-betaAG-TOCA PET/CT and [(68)Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A Prospective, Phase 2 Comparative Study.
    J Nucl Med. 2024 Feb 8:jnumed.123.266601. doi: 10.2967/jnumed.123.266601.
    >> Share

  416. HIRMAS N, Hamacher R, Sraieb M, Kessler L, et al
    Diagnostic Accuracy of (68)Ga-FAPI Versus (18)F-FDG PET in Patients with Various Malignancies.
    J Nucl Med. 2024 Feb 8:jnumed.123.266652. doi: 10.2967/jnumed.123.266652.
    >> Share

  417. GONDRY O, Caveliers V, Xavier C, Raes L, et al
    Phase II Trial Assessing the Repeatability and Tumor Uptake of [(68)Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma.
    J Nucl Med. 2024;65:178-184.
    >> Share

  418. OH M, Oh SJ, Lee SJ, Oh JS, et al
    One-Year Longitudinal Changes in Tau Accumulation on [(18)F]PI-2620 PET in the Alzheimer Spectrum.
    J Nucl Med. 2024 Feb 1:jnumed.123.265893. doi: 10.2967/jnumed.123.265893.
    >> Share

  419. SOULEN MC, Rilling WS
    Clinical Outcomes After Personalized Dosimetry for (90)Y Radioembolization of Advanced Hepatocellular Carcinoma: Defining the Role of a Device in a Pharma-Centric Landscape.
    J Nucl Med. 2024;65:270-271.
    >> Share

  420. AL MANSOUR L, De Mestier L, Haissaguerre M, Afchain P, et al
    Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by (177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Networ
    J Nucl Med. 2024;65:258-263.
    >> Share

  421. HAMACHER R, Pabst KM, Cheung PF, Heilig CE, et al
    Fibroblast Activation Protein alpha-Directed Imaging and Therapy of Solitary Fibrous Tumor.
    J Nucl Med. 2024;65:252-257.
    >> Share

  422. WAGEMANS MEHM, Kunnen B, Stella M, van Rooij R, et al
    Comparison of 3 Different Therapeutic Particles in Radioembolization of Locally Advanced Intrahepatic Cholangiocarcinoma.
    J Nucl Med. 2024;65:272-278.
    >> Share

  423. HE Y, Kramer SD, Grether U, Wittwer MB, et al
    Identification of (R)-[(18)F]YH134 for Monoacylglycerol Lipase Neuroimaging and Exploration of Its Use for Central Nervous System and Peripheral Drug Development.
    J Nucl Med. 2024;65:300-305.
    >> Share

  424. MILEVA M, Marin G, Levillain H, Artigas C, et al
    Prediction of (177)Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study.
    J Nucl Med. 2024;65:236-244.
    >> Share

  425. GIRUM KB, Cottereau AS, Vercellino L, Rebaud L, et al
    Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial.
    J Nucl Med. 2024;65:313-319.
    >> Share

  426. CHIESA C, Bagnalasta M, Maccauro M
    Good Voxel Dosimetry with a Simplified Study Design Resulted in Improvable Safety Limits.
    J Nucl Med. 2024;65:331-332.
    >> Share

    January 2024
  427. GU B, Yang Z, Du X, Xu X, et al
    Imaging of Tumor Stroma Using (68)Ga-FAPI PET/CT to Improve Diagnostic Accuracy of Primary Tumors in Head and Neck Cancer of Unknown Primary: A Comparative Imaging Trial.
    J Nucl Med. 2024 Jan 25:jnumed.123.266556. doi: 10.2967/jnumed.123.266556.
    >> Share

  428. KIRBY A, Graf D, Suchy M, Calvert ND, et al
    It's a Trap! Aldolase-Prescribed C(4) Deoxyradiofluorination Affords Intracellular Trapping and the Tracing of Fructose Metabolism by PET.
    J Nucl Med. 2024 Jan 25:jnumed.123.266905. doi: 10.2967/jnumed.123.266905.
    >> Share

  429. YEH R, O'Donoghue JA, Jayaprakasam VS, Mauguen A, et al
    First-in-Human Evaluation of Site-Specifically Labeled (89)Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer.
    J Nucl Med. 2024 Jan 25:jnumed.123.266392. doi: 10.2967/jnumed.123.266392.
    >> Share

  430. BUCHERT R, Szabo B, Kovacs A, Buddenkotte T, et al
    Dopamine Transporter SPECT with 12-Minute Scan Duration Using Multiple-Pinhole Collimators.
    J Nucl Med. 2024 Jan 18:jnumed.123.266276. doi: 10.2967/jnumed.123.266276.
    >> Share

  431. LIGHT A, Lazic S, Houghton K, Bayne M, et al
    Diagnostic Performance of (68)Ga-PSMA-11 PET/CT Versus Multiparametric MRI for Detection of Intraprostatic Radiorecurrent Prostate Cancer.
    J Nucl Med. 2024 Jan 11:jnumed.123.266527. doi: 10.2967/jnumed.123.266527.
    >> Share

  432. BARLATEY SL, Mignardot CG, Friedrichs-Maeder C, Schindler K, et al
    Triggered Seizures for Ictal SPECT Imaging: A Case Series and Feasibility Study.
    J Nucl Med. 2024 Jan 11:jnumed.123.266515. doi: 10.2967/jnumed.123.266515.
    >> Share

  433. KOSHKIN VS, Kumar V, Kline B, Escobar D, et al
    Initial Experience with (68)Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer.
    J Nucl Med. 2024 Jan 11:jnumed.123.266390. doi: 10.2967/jnumed.123.266390.
    >> Share

  434. UNTERRAINER LM, Memarzadeh S, Moatamed NA, Benz MR, et al
    [(68)Ga]Ga-FAPI-46 PET in a Borderline Ovarian Tumor.
    J Nucl Med. 2024 Jan 11:jnumed.123.266732. doi: 10.2967/jnumed.123.266732.
    >> Share

  435. HOPE TA, Jadvar H
    PSMA PET AUC Updates: Inclusion of rh-PSMA-7.3.
    J Nucl Med. 2024 Jan 4:jnumed.123.267042. doi: 10.2967/jnumed.123.267042.
    >> Share

  436. UNTERRAINER LM, Ruchalski K, Allen-Auerbach MS, Calais J, et al
    PSMA PET/CT Dual-Time-Point Imaging: Nice to Have or Need to Have?
    J Nucl Med. 2024 Jan 4:jnumed.123.266722. doi: 10.2967/jnumed.123.266722.
    >> Share

  437. DE WINTER RW, van Diemen PA, Schumacher SP, Jukema RA, et al
    Hemodynamic Insights into Combined Fractional Flow Reserve and Instantaneous Wave-Free Ratio Assessment Through Quantitative [(15)O]H(2)O PET Myocardial Perfusion Imaging.
    J Nucl Med. 2024 Jan 4:jnumed.123.265973. doi: 10.2967/jnumed.123.265973.
    >> Share

  438. RAHBAR K, Boegemann M
    The Imperative for Comparative Studies in Nuclear Medicine: Elevating (177)Lu-PSMA-617 in the Treatment Paradigm for mCRPC.
    J Nucl Med. 2024 Jan 4:jnumed.123.266952. doi: 10.2967/jnumed.123.266952.
    >> Share

  439. LI X, Lu N, Lin L, Chen Y, et al
    (18)F-FAPI-04 Outperforms (18)F-FDG PET/CT in Clinical Assessments of Patients with Pancreatic Adenocarcinoma.
    J Nucl Med. 2024 Jan 4:jnumed.123.266283. doi: 10.2967/jnumed.123.266283.
    >> Share

  440. ZHAO L, Pang Y, Fang J, Chen J, et al
    Design, Preclinical Evaluation, and Clinical Translation of (68)Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma.
    J Nucl Med. 2024 Jan 4:jnumed.123.266183. doi: 10.2967/jnumed.123.266183.
    >> Share

  441. STRUNK M, Heo GS, Hess A, Luehmann H, et al
    Toward Quantitative Multisite Preclinical Imaging Studies in Acute Myocardial Infarction: Evaluation of the Immune-Fibrosis Axis.
    J Nucl Med. 2024 Jan 4:jnumed.123.266526. doi: 10.2967/jnumed.123.266526.
    >> Share

  442. SCHILHAM MGM, Somford DM, Kusters-Vandevelde HVN, Hermsen R, et al
    Prostate-Specific Membrane Antigen-Targeted Radioguided Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients with a Suspicion of Locoregional Lymph Node Metastases: The DETECT Trial.
    J Nucl Med. 2024 Jan 4:jnumed.123.266495. doi: 10.2967/jnumed.123.266495.
    >> Share

  443. SPEKTOR AM, Gutjahr E, Lang M, Glatting FM, et al
    Immunohistochemical FAP Expression Reflects (68)Ga-FAPI PET Imaging Properties of Low- and High-Grade Intraductal Papillary Mucinous Neoplasms and Pancreatic Ductal Adenocarcinoma.
    J Nucl Med. 2024;65:52-58.
    >> Share

  444. PAPPAS V, Czernin J
    Expanding the Mission and Influence of SNMMI: A Conversation Between Johannes Czernin and Virginia Pappas About Her Career in SNMMI Leadership.
    J Nucl Med. 2024;65:1-3.
    >> Share

  445. POPLAWSKI SE, Hallett RM, Dornan MH, Novakowski KE, et al
    Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-alpha (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors.
    J Nucl Med. 2024;65:100-108.
    >> Share

  446. MALIHA PG, Hotta M, Czernin J, Calais J, et al
    Characterizing Normal Variant [(68)Ga]Ga-FAPI-46 Uptake in the Epididymis.
    J Nucl Med. 2024;65:59-62.
    >> Share

  447. LUTHRIA G, Baratto L, Adams L, Morakote W, et al
    Increased Metabolic Activity of the Thymus and Lymph Nodes in Pediatric Oncology Patients After Coronavirus Disease 2019 Vaccination.
    J Nucl Med. 2024;65:22-24.
    >> Share

  448. ENKE JS, Reitsam NG, Grosser B, Kircher M, et al
    C-X-C Motif Chemokine Receptor 4-Directed Scintigraphy of Multiple Myeloma Using [(99m)Tc]Tc-PentixaTec.
    J Nucl Med. 2024;65:163-164.
    >> Share

    December 2023
  449. CHAN DL, Hayes AR, Karfis I, Conner A, et al
    [(18)F]FDG PET/CT-Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study.
    J Nucl Med. 2023 Dec 21:jnumed.123.266346. doi: 10.2967/jnumed.123.266346.
    >> Share

  450. MIAO Y, Feng R, Yu T, Guo R, et al
    Value of (68)Ga-FAPI-04 and (18)F-FDG PET/CT in Early Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.
    J Nucl Med. 2023 Dec 21:jnumed.123.266403. doi: 10.2967/jnumed.123.266403.
    >> Share

  451. VENTURA D, Dittmann M, Buther F, Schafers M, et al
    Diagnostic Performance of [(18)F]TFB PET/CT Compared with Therapeutic Activity [(131)I]Iodine SPECT/CT and [(18)F]FDG PET/CT in Recurrent Differentiated Thyroid Carcinoma.
    J Nucl Med. 2023 Dec 21:jnumed.123.266513. doi: 10.2967/jnumed.123.266513.
    >> Share

  452. DIERKS A, Gable A, Rinscheid A, Wienand G, et al
    First Safety and Efficacy Data with the Radiohybrid (177)Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer.
    J Nucl Med. 2023 Dec 21:jnumed.123.266741. doi: 10.2967/jnumed.123.266741.
    >> Share

  453. BARTLETT EA, Lesanpezeshki M, Anishchenko S, Shkolnik I, et al
    Dynamic Human Brain Imaging with a Portable PET Camera: Comparison to a Standard Scanner.
    J Nucl Med. 2023 Dec 14:jnumed.122.265309. doi: 10.2967/jnumed.122.265309.
    >> Share

  454. FETTAHOGLU A, Zhao M, Khalighi M, Vossler H, et al
    Early-Frame [(18)F]Florbetaben PET/MRI for Cerebral Blood Flow Quantification in Patients with Cognitive Impairment: Comparison to an [(15)O]Water Gold Standard.
    J Nucl Med. 2023 Dec 7:jnumed.123.266273. doi: 10.2967/jnumed.123.266273.
    >> Share

  455. MANKOFF D, Balogova S, Dunnwald L, Dehdashti F, et al
    Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16alpha-[(18)F]Fluoro-17beta-Estradiol PET.
    J Nucl Med. 2023 Dec 7:jnumed.123.266938. doi: 10.2967/jnumed.123.266938.
    >> Share

  456. NADEL HR
    A Strategic Approach to Advancing Nuclear Medicine and Molecular Imaging.
    J Nucl Med. 2023;64:1843-1844.
    >> Share

  457. BLAZHENETS G, Soleimani-Meigooni DN, Thomas W, Mundada N, et al
    [(18)F]PI-2620 Binding Patterns in Patients with Suspected Alzheimer Disease and Frontotemporal Lobar Degeneration.
    J Nucl Med. 2023;64:1980-1989.
    >> Share

  458. FANI M, Nicolas GP
    (61)Cu-Labeled Radiotracers: Alternative or Choice?
    J Nucl Med. 2023;64:1855-1857.
    >> Share

    November 2023
  459. EMMETT L, Papa N, Counter W, Calais J, et al
    Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database.
    J Nucl Med. 2023 Nov 30:jnumed.123.266164. doi: 10.2967/jnumed.123.266164.
    >> Share

  460. WANG F, Liu C, Vidal I, Mana-Ay M, et al
    Comparison of Multiple Segmentation Methods for Volumetric Delineation of Primary Prostate Cancer with Prostate-Specific Membrane Antigen-Targeted (18)F-DCFPyL PET/CT.
    J Nucl Med. 2023 Nov 30:jnumed.123.266005. doi: 10.2967/jnumed.123.266005.
    >> Share

  461. DING J, Li X, Liu S, Gao Y, et al
    Clinical Value of (68)Ga-Pentixafor PET/CT in Subtype Diagnosis of Primary Aldosteronism Patients with Adrenal Micronodules.
    J Nucl Med. 2023 Nov 30:jnumed.123.266061. doi: 10.2967/jnumed.123.266061.
    >> Share

  462. KLUGE K, Einspieler H, Haberl D, Spielvogel C, et al
    Examining the Relationship and Prognostic Significance of Cell-Free DNA Levels and the PSMA-Positive Tumor Volume in Men with Prostate Cancer: A Retrospective-Prospective [(68)Ga]Ga-PSMA-11 PET/CT Study.
    J Nucl Med. 2023 Nov 30:jnumed.123.266158. doi: 10.2967/jnumed.123.266158.
    >> Share

  463. PUUVUORI E, Shen Y, Hulsart-Billstrom G, Mitran B, et al
    Noninvasive PET Detection of CD69-Positive Immune Cells Before Signs of Clinical Disease in Inflammatory Arthritis.
    J Nucl Med. 2023 Nov 30:jnumed.123.266336. doi: 10.2967/jnumed.123.266336.
    >> Share

  464. NDLOVU H, Lawal I, Mokoala K, Disenyane D, et al
    Imaging PARP Upregulation with [(123)I]I-PARPi SPECT/CT in Small Cell Neuroendocrine Carcinoma.
    J Nucl Med. 2023 Nov 30:jnumed.123.266348. doi: 10.2967/jnumed.123.266348.
    >> Share

  465. DOERING E, Antonopoulos G, Hoenig M, van Eimeren T, et al
    MRI or (18)F-FDG PET for Brain Age Gap Estimation: Links to Cognition, Pathology, and Alzheimer Disease Progression.
    J Nucl Med. 2023 Nov 30:jnumed.123.265931. doi: 10.2967/jnumed.123.265931.
    >> Share

  466. KURONUMA K, Wei CC, Singh A, Lemley M, et al
    Automated Motion Correction for Myocardial Blood Flow Measurements and Diagnostic Performance of (82)Rb PET Myocardial Perfusion Imaging.
    J Nucl Med. 2023 Nov 30:jnumed.123.266208. doi: 10.2967/jnumed.123.266208.
    >> Share

  467. QUAN Z, Han Z, Yang Y, Wang J, et al
    Noninvasive Monitoring of Immunotherapy in Lung Cancer by Lymphocyte Activation Gene 3 PET Imaging of Tumor-Infiltrating Lymphocytes.
    J Nucl Med. 2023 Nov 16:jnumed.123.266002. doi: 10.2967/jnumed.123.266002.
    >> Share

  468. KESSLER L, Hirmas N, Pabst KM, Hamacher R, et al
    (68)Ga-Labeled Fibroblast Activation Protein Inhibitor ((68)Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the (68)Ga-FAPI PET Observational Trial.
    J Nucl Med. 2023 Nov 16:jnumed.122.264827. doi: 10.2967/jnumed.122.264827.
    >> Share

  469. NAMMAS W, Paunonen C, Teuho J, Siekkinen R, et al
    Imaging of Myocardial alpha(v)beta(3) Integrin Expression for Evaluation of Myocardial Injury After Acute Myocardial Infarction.
    J Nucl Med. 2023 Nov 16:jnumed.123.266148. doi: 10.2967/jnumed.123.266148.
    >> Share

  470. BALAJI V, Song TA, Malekzadeh M, Heidari P, et al
    Artificial Intelligence for PET and SPECT Image Enhancement.
    J Nucl Med. 2023 Nov 9:jnumed.122.265000. doi: 10.2967/jnumed.122.265000.
    >> Share

  471. GUNTHER T, Holzleitner N, Viering O, Beck R, et al
    Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [(68)Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer.
    J Nucl Med. 2023 Nov 9:jnumed.123.266537. doi: 10.2967/jnumed.123.266537.
    >> Share

  472. CARLIER T, Frecon G, Mateus D, Rizkallah M, et al
    Prognostic Value of (18)F-FDG PET Radiomics Features at Baseline in PET-Guided Consolidation Strategy in Diffuse Large B-Cell Lymphoma: A Machine-Learning Analysis from the GAINED Study.
    J Nucl Med. 2023 Nov 9:jnumed.123.265872. doi: 10.2967/jnumed.123.265872.
    >> Share

  473. CHEN L, Zheng S, Chen L, Xu S, et al
    (68)Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study.
    J Nucl Med. 2023 Nov 2:jnumed.123.266079. doi: 10.2967/jnumed.123.266079.
    >> Share

  474. REZAZADEH F, Kilcline AP, Viola NT
    Imaging Agents for PET of Inflammatory Bowel Disease: A Review.
    J Nucl Med. 2023 Nov 2:jnumed.123.265935. doi: 10.2967/jnumed.123.265935.
    >> Share

  475. VIERING O, Gunther T, Holzleitner N, Dierks A, et al
    CCK(2) Receptor-Targeted PET/CT in Medullary Thyroid Cancer Using [(68)Ga]Ga-DOTA-CCK-66.
    J Nucl Med. 2023 Nov 2:jnumed.123.266380. doi: 10.2967/jnumed.123.266380.
    >> Share

  476. GEBHART G
    (18)F-FDG PET "Metabolic Response" to Neoadjuvant Systemic Therapy for Breast Cancer: Quo Vadis?
    J Nucl Med. 2023;64:1697-1698.
    >> Share

  477. KNUUTI J, Tuisku J, Karpijoki H, Iida H, et al
    Quantitative Perfusion Imaging with Total-Body PET.
    J Nucl Med. 2023;64.
    >> Share

  478. DI CARLI MF
    Future of Radionuclide Myocardial Perfusion Imaging: Transitioning from SPECT to PET.
    J Nucl Med. 2023;64.
    >> Share

  479. BENGEL FM, Di Carli MF
    The Evolution of Cardiac Nuclear Imaging.
    J Nucl Med. 2023;64.
    >> Share

  480. ROLL W, Faust A, Hermann S, Schafers M, et al
    Infection Imaging: Focus on New Tracers?
    J Nucl Med. 2023;64.
    >> Share

  481. LI EJ, Lopez JE, Spencer BA, Abdelhafez Y, et al
    Total-Body Perfusion Imaging with [(11)C]-Butanol.
    J Nucl Med. 2023;64:1831-1838.
    >> Share

    October 2023
  482. KAYAL G, Barbosa N, Calderon Marin C, Ferrer L, et al
    Quality Assurance Considerations in Radiopharmaceutical Therapy Dosimetry Using PLANETDose: An International Atomic Energy Agency Study.
    J Nucl Med. 2023 Oct 26:jnumed.122.265340. doi: 10.2967/jnumed.122.265340.
    >> Share

  483. MAULER J, Lohmann P, Maudsley AA, Sheriff S, et al
    Diagnostic Accuracy of MR Spectroscopic Imaging and (18)F-FET PET for Identifying Glioma: A Biopsy-Controlled Hybrid PET/MRI Study.
    J Nucl Med. 2023 Oct 26:jnumed.123.265868. doi: 10.2967/jnumed.123.265868.
    >> Share

  484. XU W, Cai J, Peng T, Meng T, et al
    Fibroblast Activation Protein-Targeted PET/CT with (18)F-Fibroblast Activation Protein Inhibitor-74 for Evaluation of Gastrointestinal Cancer: Comparison with (18)F-FDG PET/CT.
    J Nucl Med. 2023 Oct 26:jnumed.123.266329. doi: 10.2967/jnumed.123.266329.
    >> Share

  485. LASCHINSKY C, Theurer S, Herold T, Rawitzer J, et al
    Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma.
    J Nucl Med. 2023 Oct 26:jnumed.123.266044. doi: 10.2967/jnumed.123.266044.
    >> Share

  486. KAIREMO K, Czernin J
    Advancing Nuclear Medicine at the Multiomics Intersection: Johannes Czernin Discusses Innovation and Translation with Kalevi Kairemo.
    J Nucl Med. 2023 Oct 19:jnumed.123.266793. doi: 10.2967/jnumed.123.266793.
    >> Share

  487. YAMAGISHI S, Miwa K, Kamitaki S, Anraku K, et al
    Performance Characteristics of a New-Generation Digital Bismuth Germanium Oxide PET/CT System, Omni Legend 32, According to NEMA NU 2-2018 Standards.
    J Nucl Med. 2023 Oct 19:jnumed.123.266140. doi: 10.2967/jnumed.123.266140.
    >> Share

  488. LI X, Ye J, Wang J, Quan Z, et al
    First-in-Humans PET Imaging of KRAS(G12C) Mutation Status in Non-Small Cell Lung and Colorectal Cancer Patients Using [(18)F]PFPMD.
    J Nucl Med. 2023 Oct 12:jnumed.123.265715. doi: 10.2967/jnumed.123.265715.
    >> Share

  489. WATABE T, Kabayama K, Naka S, Yamamoto R, et al
    Immuno-PET and Targeted alpha-Therapy Using Anti-Glypican-1 Antibody Labeled with (89)Zr or (211)At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma.
    J Nucl Med. 2023 Oct 12:jnumed.123.266313. doi: 10.2967/jnumed.123.266313.
    >> Share

  490. AL-TOUBAH T, Montilla-Soler J, El-Haddad G, Haider M, et al
    Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of DOTATATE PET Scans.
    J Nucl Med. 2023 Oct 5:jnumed.123.266185. doi: 10.2967/jnumed.123.266185.
    >> Share

  491. DUELL J, Buck AK, Hartrampf PE, Schlotelburg W, et al
    Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma.
    J Nucl Med. 2023 Oct 5:jnumed.123.266074. doi: 10.2967/jnumed.123.266074.
    >> Share

  492. SCHEUERMANN JS, Pryma DA
    Choosing the Right Metrics for Evaluation of Radiopharmaceutical Therapy Dosimetry Methodologies.
    J Nucl Med. 2023;64:1617-1618.
    >> Share

  493. CHICHEPORTICHE A, Sason M, Zidan M, Godefroy J, et al
    Impact of Single-Time-Point Estimates of (177)Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles.
    J Nucl Med. 2023;64:1610-1616.
    >> Share

  494. GANZ PA, Czernin J
    Pioneering Research on Cancer Quality of Life and Outcomes: Johannes Czernin Discusses a Half-Century of Whole-Patient Focus with Patricia A. Ganz.
    J Nucl Med. 2023;64:1506-1508.
    >> Share

  495. MELLHAMMAR E, Dahlbom M, Vilhelmsson-Timmermand O, Strand SE, et al
    Tumor Control Probability and Small-Scale Monte Carlo Dosimetry: Effects of Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical Therapy.
    J Nucl Med. 2023;64:1632-1637.
    >> Share

  496. KOLLER L, Joksch M, Schwarzenbock S, Kurth J, et al
    Preclinical Comparison of the (64)Cu- and (68)Ga-Labeled GRPR-Targeted Compounds RM2 and AMTG, as Well as First-in-Humans [(68)Ga]Ga-AMTG PET/CT.
    J Nucl Med. 2023;64:1654-1659.
    >> Share

  497. COOK BE, Nag S, Arakawa R, Lin EY, et al
    Development of a PET Tracer for OGA with Improved Kinetics in the Living Brain.
    J Nucl Med. 2023;64:1588-1593.
    >> Share

  498. HERINGTON J, McCradden MD, Creel K, Boellaard R, et al
    Ethical Considerations for Artificial Intelligence in Medical Imaging: Deployment and Governance.
    J Nucl Med. 2023;64:1509-1515.
    >> Share

    September 2023
  499. SHAGERA QA, Karfis I, Kristanto P, Spyridon S, et al
    PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors.
    J Nucl Med. 2023 Sep 28:jnumed.123.265874. doi: 10.2967/jnumed.123.265874.
    >> Share

  500. HABERBOSCH L, Gillett D, MacFarlane J, Koulouri O, et al
    Dual Role for l-[Methyl-(11)C]-Methionine PET in Acromegaly: Confirming Remission and Detecting Recurrence.
    J Nucl Med. 2023 Sep 28:jnumed.123.266446. doi: 10.2967/jnumed.123.266446.
    >> Share

  501. CONSTANTINESCU CC, Brown T, Wang S, Yin W, et al
    Clinical Characterization of [(18)F]T-008, a Cholesterol 24-Hydroxylase PET Ligand: Dosimetry, Kinetic Modeling, Variability, and Soticlestat Occupancy.
    J Nucl Med. 2023 Sep 28:jnumed.123.265912. doi: 10.2967/jnumed.123.265912.
    >> Share

  502. ALBERTO S, Ordonez AA, Arjun C, Aulakh GK, et al
    The Development and Validation of Radiopharmaceuticals Targeting Bacterial Infection.
    J Nucl Med. 2023 Sep 28:jnumed.123.265906. doi: 10.2967/jnumed.123.265906.
    >> Share

  503. CHAN CY, Chen Z, Guibbal F, Dias G, et al
    [(123)I]CC1: A PARP-Targeting, Auger Electron-Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer.
    J Nucl Med. 2023 Sep 28:jnumed.123.265429. doi: 10.2967/jnumed.123.265429.
    >> Share

  504. SCHMIDKONZ C, Atzinger A, Ramming A, Kuwert T, et al
    FAPI PET/CT Immune-Fibrosis Imaging for New Insights into Rheumatologic Disorders.
    J Nucl Med. 2023 Sep 21:jnumed.123.266182. doi: 10.2967/jnumed.123.266182.
    >> Share

  505. KLUGE K, Haberl D, Einspieler H, Rasul S, et al
    Antihormonal-Treatment Status Affects (68)Ga-PSMA-HBED-CC PET Biodistribution in Patients with Prostate Cancer.
    J Nucl Med. 2023 Sep 21:jnumed.123.265980. doi: 10.2967/jnumed.123.265980.
    >> Share

  506. ITTI E, Blanc-Durand P, Berriolo-Riedinger A, Kanoun S, et al
    Validation of the DeltaSUV(max) for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial.
    J Nucl Med. 2023 Sep 21:jnumed.123.265871. doi: 10.2967/jnumed.123.265871.
    >> Share

  507. DEMMERT TT, Pomykala KL, Lanzafame H, Pabst KM, et al
    Oncologic Staging with (68)Ga-FAPI PET/CT Demonstrates a Lower Rate of Nonspecific Lymph Node Findings Than (18)F-FDG PET/CT.
    J Nucl Med. 2023 Sep 21:jnumed.123.265751. doi: 10.2967/jnumed.123.265751.
    >> Share

  508. ROGASCH JMM, Metzger G, Preisler M, Galler M, et al
    ChatGPT: Can You Prepare My Patients for [(18)F]FDG PET/CT and Explain My Reports?
    J Nucl Med. 2023 Sep 14:jnumed.123.266114. doi: 10.2967/jnumed.123.266114.
    >> Share

  509. ALTENA R, Af Buren S, Tran T, Axelsson R, et al
    HER2-Low Breast Cancer Can Be Visualized by HER2 PET.
    J Nucl Med. 2023 Sep 14:jnumed.123.266101. doi: 10.2967/jnumed.123.266101.
    >> Share

  510. SEBAN RD
    Reply to: HER2-Low Breast Cancer Can Be Visualized by HER2 PET.
    J Nucl Med. 2023 Sep 14:jnumed.123.266490. doi: 10.2967/jnumed.123.266490.
    >> Share

  511. GEORGOULIAS P, Angelidis G, Koukouraki S, Koutsikos J, et al
    Debating the Future of Nuclear Medicine: The Greek Experience.
    J Nucl Med. 2023 Sep 14:jnumed.123.266646. doi: 10.2967/jnumed.123.266646.
    >> Share

  512. GOGOLA A, Lopresti BJ, Tudorascu D, Snitz B, et al
    Biostatistical Estimation of Tau Threshold Hallmarks (BETTH) Algorithm for Human Tau PET Imaging Studies.
    J Nucl Med. 2023 Sep 14:jnumed.123.265941. doi: 10.2967/jnumed.123.265941.
    >> Share

  513. KOERBER SA, Rohrich M, Walkenbach L, Liermann J, et al
    Impact of (68)Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers.
    J Nucl Med. 2023 Sep 7:jnumed.123.266046. doi: 10.2967/jnumed.123.266046.
    >> Share

  514. MURTHY V, Gafita A, Thin P, Nguyen K, et al
    Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with (177)Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis.
    J Nucl Med. 2023 Sep 7:jnumed.122.265155. doi: 10.2967/jnumed.122.265155.
    >> Share

  515. SUNDERLAND JJ, Graves SA, York DM, Mundt CA, et al
    Response to "Critique and Discussion of 'Multicenter Evaluation of Frequency and Impact of Activity Infiltration in PET Imaging, Including Microscale Modeling of Skin-Absorbed Dose'".
    J Nucl Med. 2023 Sep 7:jnumed.123.266596. doi: 10.2967/jnumed.123.266596.
    >> Share

  516. KARIMZADEH A, Soeiro P, Feuerecker B, Hecker CS, et al
    Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of (177)Lu-PSMA I&T.
    J Nucl Med. 2023 Sep 7:jnumed.123.265878. doi: 10.2967/jnumed.123.265878.
    >> Share

  517. MANKOFF D
    The Future of Nuclear Medicine.
    J Nucl Med. 2023;64:1329-1330.
    >> Share

  518. KRAEBER-BODERE F, Jamet B, Bezzi D, Zamagni E, et al
    New Developments in Myeloma Treatment and Response Assessment.
    J Nucl Med. 2023;64:1331-1343.
    >> Share

  519. WANG C, Peterson AB, Wong KK, Roseland ME, et al
    Single-Time-Point Imaging for Dosimetry After [(177)Lu]Lu-DOTATATE: Accuracy of Existing Methods and Novel Data-Driven Models for Reducing Sensitivity to Time-Point Selection.
    J Nucl Med. 2023;64:1463-1470.
    >> Share

  520. HARTLAPP I, Hartrampf PE, Serfling SE, Wild V, et al
    CXCR4-Directed Imaging and Endoradiotherapy in Desmoplastic Small Round Cell Tumors.
    J Nucl Med. 2023;64:1424-1430.
    >> Share

  521. PANG Y, Zhao L, Fang J, Chen J, et al
    Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy.
    J Nucl Med. 2023;64:1449-1455.
    >> Share

  522. AHMAD AA, Ghim M, Toczek J, Neishabouri A, et al
    Multimodality Imaging of Aortic Valve Calcification and Function in a Murine Model of Calcific Aortic Valve Disease and Bicuspid Aortic Valve.
    J Nucl Med. 2023;64:1487-1494.
    >> Share

    August 2023
  523. ALAN-SELCUK N, Beydagi G, Demirci E, Ocak M, et al
    Clinical Experience with [(225)Ac]Ac-PSMA Treatment in Patients with [(177)Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2023 Aug 24:jnumed.123.265546. doi: 10.2967/jnumed.123.265546.
    >> Share

  524. EIFER M, Alipour R, Hofman MS, Ravi Kumar AS, et al
    Out with the Old, in with the New: Can We Bridge the Gap Between Clinical Trial Results Based on Bone Scans and the Era of Modern Prostate Cancer Imaging?
    J Nucl Med. 2023 Aug 17:jnumed.123.266025. doi: 10.2967/jnumed.123.266025.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016